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Avant propos 
 
Certains médicaments (tableau 1) présentent des différences individuelles considérables en 
terme d’efficacité et de toxicité. Ceci complique considérablement la définition d’une relation 
dose/effet (1). Le monitoring thérapeutique 
consiste à surveiller les effets d’un traitement 
dans le but de réduire les variabilités de la 
réponse thérapeutique (1-5). Cette variabilité 
dépendant à la fois des propriétés du principe 
actif (pharmacocinétique et 
pharmacodynamie) et de l’état clinique du 
patient (insuffisance hépatique, rénale, …) 
(6).  
 
Dans le cas de médicaments 
présentant une marge thérapeutique étroite, 
ces disparités individuelles font qu’une 
posologie idéale chez certains patients peut 
être toxique ou inefficace chez d’autres (6,7). 
Dans ce cas précis le monitoring 
thérapeutique constitue un outil essentiel à la 
disposition du praticien pour individualiser le 
traitement. Lorsque les effets d’un traitement 
(thérapeutiques ou toxiques) ne sont pas 
aisément visibles ou quantifiables par le 
patient ou le praticien (6) (par exemple : 
traitements prophylactiques antiépileptiques, 
antiarythmiques, stabilisateurs de l’humeur, 
etc…), le monitoring permet de confirmer un 
bénéfice thérapeutique et d’éviter des effets 
secondaires (7). Le monitoring thérapeutique 
permet aussi de contrôler la compliance du 
Tableau 1: Principes actifs couramment monitorisés. 
Antalgiques, Antipyrétiques / Anti-inflammatoires
• Paracétamol 
• Salicylés 
Antibiotiques 
• Aminosides 
o Amikacine 
o Gentamicine 
o Nétilmicine 
o Tobramycine 
• Vancomycine 
Antiépileptiques:  
• Carbamazépine 
• Ethosuximide 
• Phénobarbital 
• Phénytoïne 
• Primidone 
• Acide valproïque 
Cytotoxiques 
• Méthotrexate 
Bronchodilatateurs 
• Théophylline 
Insuffisance cardiaque / Antiarythmiques 
• Digitaliques 
o Digoxine 
o Digitoxine 
• Antiarhythmiques 
o Disopyramide 
o Lidocaïne 
o Procaïnamide/NAPA 
o Quinidine 
Immunosuppresseurs 
• Ciclosporine A 
Antidépresseurs / Stabilisateurs de l’humeur 
• Antidépresseurs imipraminiques 
o Amitriptyline 
o Désipramine 
o Imipramine 
o Nortriptyline 
• Lithium 
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patient au traitement, d’établir la cause d’échecs thérapeutiques ou de surveiller la modification d’un 
traitement (interférence médicamenteuse, médicament ayant une pharmacocinétique non linéaire, 
etc…) (6-8). 
 
Dès lors que les concentrations systémiques du médicament sont en relation étroite avec les 
effets thérapeutiques et secondaires, ce contrôle est classiquement réalisé par prise de sang. La 
fréquence du monitoring dépend beaucoup de la situation clinique du patient (6). Un monitoring 
régulier est requis lors de l’établissement ou de la modification du traitement. Un contrôle périodique 
moins fréquent est généralement prescrit pour les patients traités sur le long terme. Néanmoins, un 
contrôle immédiat peut-être décidé en cas d’échecs thérapeutiques, d’effets secondaires, de 
modifications physiologiques (par exemple : maladie, grossesse) risquant de perturber la 
pharmacocinétique du médicament ou encore lorsqu’une non-compliance est suspectée. 
 
Des méthodes moins invasives que la prise de sang offrent des bénéfices évidents : moins 
douloureuses du point de vue du patient, elles contribuent davantage au confort du patient lorsqu’un 
usage ambulatoire est possible. D’un point de vue médical, elles facilitent le contrôle chez les patients, 
diminuent les risques de complication (hématomes, infections,…) et rendent possible un monitoring 
plus fréquent permettant un meilleur suivi thérapeutique. Ces techniques non-invasives sont 
particulièrement utiles chez certaines populations (pédiatriques, gériatriques, soins intensifs, etc…) 
dont les facteurs physiologiques ou pathologiques perturbent la pharmacocinétique des médicaments 
et nécessiteraient par conséquent un monitoring plus fréquent (1,9-13). Pourtant, cet objectif reste trop 
souvent inaccessible par prise de sang pour diverses raisons : fréquence, volume de prélèvement, 
etc…(14). De plus le monitoring est souvent indispensable chez ces populations exprimant 
difficilement les effets bénéfiques ou secondaires d’un traitement. D’autant que l’information 
pharmacocinétique disponible reste limitée obligeant souvent le praticien à extrapoler les valeurs 
connues (15). Disposer d’outils non-invasifs favoriserait alors la réalisation d’études 
pharmacocinétiques dans ces populations sensibles (16-18). 
 
Différentes stratégies non-invasives ont été proposées. Certaines techniques limitent le nombre 
de prélèvement par l’usage d’outils statistiques maximisant les informations obtenues d’un nombre 
limité de prélèvements (6,19). D’autres totalement non-invasives s’intéressent aux fluides et matrices 
biologiques alternatives (10,20,21). Dans le cas de l’urine, les cheveux et la sueur, ces applications se 
limitent à la détection de composés en toxicologie ou médecine légale (22-25). La salive fut sans doute 
l'alternative la plus étudiée à des fins quantitatives pour le monitoring thérapeutique (26-30). 
Cependant, au regard d’une grande variabilité inter-individuelle des fractions extraites et d’une forte 
sensibilité à de nombreux facteurs (pH, débit de sécrétion salivaire, etc …) son utilisation reste limitée 
(10,30). 
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La peau représente une alternative séduisante par sa surface importante et son accès facile, 
mais son excellente fonction barrière limite considérablement le transport des molécules polaires et 
chargées. Des études menées in-vitro et in-vivo, ont pourtant mis en évidence la diffusion 
transdermique de certains principes actifs (31-33). La lenteur du processus d’extraction 
(indistinctement diffusion passive et sudation) exige de concentrer le médicament dans un patch 
pendant plus de 10 h. Les résultats ont montré une grande variabilité de la diffusion passive 
transdermique, ce qui limite considérablement son utilisation pour un usage en monitoring 
thérapeutique (34,35). Diverses approches ont été proposées dans le but d’augmenter les quantités 
extraites (36). Ces méthodes perturbent la fonction barrière de la peau de manière plus ou moins 
transitoires et réversibles par un effet mécanique (sonophorèse, microaiguilles), électrique 
(ionophorèse, électroporation) ou chimique (36-41). 
 
Ce projet à pour objectif d’évaluer les capacités de l’ionophorèse pour le monitoring non-
invasif des médicaments au travers de la peau. Un faible courant électrique (< 0,5 mA/cm2) appliqué à 
la surface de la peau permet de faciliter le passage transdermique des molécules (42). Parce que le 
champ électrique agit directement sur les molécules transportées et non sur la barrière cutanée, 
l’ionophorèse inversée offre un meilleur contrôle du transport et une moindre irritation de la peau que 
les autres techniques citées précédemment. L’ionophorèse est un processus actif qui permet à la fois 
l’administration et l’extraction de composés (42). L’ionophorèse inversée, qui permet l’extraction 
transdermique, fut développée intensivement pour le dosage de la glycémie, et plus récemment pour 
les dosages biologiques de la phenylalanine et de l’urée (43-47). Deux études in-vitro d’extraction de 
la clonidine, la théophylline et l’acide valproïque (45,48) ont mis en évidence le potentiel de la 
technique pour le monitoring thérapeutique. 
 
Dans le but d’étudier les capacités de l’ionophorèse inversée pour le monitoring thérapeutique, 
deux principes actifs ont été choisis : la phénytoïne et le lithium. Puisqu’il est établi que l’extraction 
ionophorètique dépend, entre autre, des propriétés physico-chimiques des molécules, ces deux 
principes actifs sont très différents (Tableau 2) (49,50). La phénytoïne de taille moléculaire importante 
présente un caractère lipophile, une 
forte liaison aux protéines 
plasmatiques ainsi qu’une ionisation 
négative et partielle qui permet son 
transport par électrorépulsion et 
électroosmose. Le lithium est un 
cation de faible masse moléculaire, 
fortement mobile et quinze fois plus concentré dans le sang que la phénytoïne. Le lithium constitue 
l’un des meilleurs candidats pour un monitoring thérapeutique par ionophorèse.  
Tableau 2 : Propriétés de la phénytoïne et du lithium 
 Phénytoïne Lithium 
Classe thérapeutique Anti-épileptique Stabilisateur  
de l’humeur 
Poids moléculaire (g/mol) 252 7 
Lipophilie (Log P) 2.5 - 
Marge thérapeutique (µM) 40-80 500-1400 
Fraction libre 10% 100% 
Charge (% ionisation) Négative (12%) 
Neutre (88%) 
Positive (100%) 
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Dans ce projet, les études menées in vitro et in vivo, (a) établissent la relation entre l’extraction 
ionophorètique et les concentrations subdermiques ou sériques. (b) Avec la phénytoïne illustrant le cas 
d’un principe actif fortement lié aux protéines plasmatiques, une étude in vitro démontre l’accès direct 
de l’ionophorèse à la fraction libre des principes actifs. (c) Avec le lithium, une étude évalue l’aptitude 
de la technique à mener des études pharmacocinétiques. (d) Toutes ces études font la preuve, in vitro 
et in-vivo, du concept d’auto-calibration de la méthode par un standard interne. 
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Structure de la thèse 
 
La thèse est structurée en deux parties. La première partie est une revue de la littérature sur le 
sujet de l’ionophorèse inversée pour le monitoring transdermique non-invasif. 
 
Chapitre 1 : Dans un premier chapitre, ce manuscrit dresse un état de la technologie. Les mécanismes 
d’extraction de l’ionophorèse inversée, ses avantages et ses inconvénients, les applications et les 
récents progrès dont cette technique a fait l’objet sont décrits dans cette revue de la littérature. 
 
Dans une seconde partie expérimentale, le manuscrit s’attache à évaluer les capacités de 
l’ionophorèse inversée pour le monitoring thérapeutique non-invasif. Deux médicaments, nécessitant 
une surveillance thérapeutique périodique, ont été choisis comme modèle pour cette étude. 
 
Chapitre 2 : La phénytoïne illustre le cas d’un médicament difficilement extractible par ionophorèse 
transdermique et fortement lié aux protéines plasmatiques. Ce chapitre examine la relation de 
dépendance de l’extraction ionophorètique vis-à-vis des concentrations subdermiques (totale et libre) 
de phénytoïne. 
 
Chapitre 3 : Dans ce chapitre, le lithium est utilisé comme modèle pour l’évaluation in vitro des 
aptitudes de l’ionophorèse inversée à réaliser non-invasivement des études pharmacocinétiques.  
 
Chapitre 4 : Ce chapitre rend compte des résultats d’une étude menée chez des patients sous 
lithiothérapie. Cette étude examine la capacité de la technique à proposer une méthode alternative et 
non invasive pour la surveillance de la lithiémie chez les patients bipolaires. 
 
Chapitre 5 : Dans ce dernier chapitre du manuscrit, les auteurs proposent une optimisation de la 
formulation des matrices d’extractions ionophorètiques en vue d’applications compatibles avec les 
contraintes des essais in-vivo. 
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Chapitre 1 
 
L’ionophorèse inversée pour le monitoring transdermique non-
invasif  
Benoît Leboulanger1,2, Richard H. Guy1,2 and M. Begoña Delgado-Charro1,2 
 
1 School of Pharmacy, University of Geneva, CH-1211 Geneva 4, Switzerland  
2 Centre international de recherche et d’enseignement (“Pharmapeptides”), F-74160 Archamps, France 
 
 
 
 
Résumé 
Ce premier chapitre dresse un état de la technologie. L’ionophorèse consiste en l’application d’un 
faible courant électrique à la surface de la peau dans le but d’augmenter le transport transdermique des 
molécules polaires chargées et neutres. Le contrôle de l’électromigration et l’électroosmose, les deux 
principaux mécanismes de transport de l’ionophorèse, est rendu possible par la modification du 
courant appliqué et/ou de certains paramètres de formulation des compartiments récepteurs. Alors que 
cette approche a principalement été utilisée pour l’administration des médicaments par voie 
transdermique, l’ionophorèse inversée, permettant l’extraction de substances à la surface de la peau, a 
récemment fait l’objet d’efforts considérables. Cette revue de la littérature décrit les mécanismes 
d’extraction de l’ionophorèse inversée, ses avantages et ses inconvénients, les applications et les 
récents progrès dont cette technique a fait l’objet. 
 
Mots-clés: Ionophorèse, Électromigration, Électroosmose, Surveillance de la glycémie, Monitoring 
thérapeutique 
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Reverse iontophoresis for non-invasive transdermal 
monitoring 
Benoît Leboulanger1,2, Richard H. Guy1,2 and M. Begoña Delgado-Charro1,2 
 
1 School of Pharmacy, University of Geneva, CH-1211 Geneva 4, Switzerland  
2 Centre international de recherche et d’enseignement (“Pharmapeptides”), F-74160 Archamps, France 
 
 
 
 
Abstract 
Iontophoresis is the application of a small electric current to enhance the transport of both charged 
and polar, neutral compounds across the skin. Manipulation of either the total charge delivered and/or 
certain electrode formulation parameters allows control of electromigration and electroosmosis, the 
two principal mechanisms of transdermal iontophoresis. While the approach has been mainly used for 
transdermal drug delivery, “reverse iontophoresis”, by which substances are extracted to the skin 
surface, has recently been the subject of considerable effort. Glucose monitoring has been extensively 
studied and other applications, including therapeutic drug monitoring, are contributing to the 
development of the technique. An internal standard calibration procedure may ultimately render this 
novel monitoring technique completely non-invasive. 
 
Keywords: Iontophoresis, Electromigration, Electroosmosis, Glucose monitoring, Therapeutic drug 
monitoring 
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I. Introduction 
Iontophoresis involves the application of a 
small and defined electrical current to the skin. 
This process causes increased molecular 
transport through the skin and has found 
application, therefore, in transdermal drug 
delivery [1]. The concept is not new, however; 
the basic mechanisms were clearly appreciated 
by Leduc [2,3] in 1900. Nevertheless, it is only 
now that approved iontophoretic drug delivery 
systems are finally reaching the market [4].  
The symmetry of iontophoresis means that 
it also enables extraction of solute molecules 
from within the subdermal compartment to the 
skin surface. The potential exists, therefore, to 
use the technique for clinical chemistry 
without blood sampling. Applications that may 
be envisaged include general blood chemistry, 
glucose monitoring, the detection of diagnostic 
markers, and therapeutic drug monitoring [4]. 
The mechanism of extraction involves either 
electromigration of charged species to the 
electrode of opposite polarity, or 
electroosmosis of polar, neutral or zwitterionic, 
molecules to the cathode; hence for cations, 
both mechanisms are operative. 
A number of excellent reviews on 
iontophoresis and its applications have been 
published [1,3,5-9]. Here, attention is focused 
on reverse iontophoresis and its applications in 
diagnosis and monitoring. After a brief 
consideration of the basics underlying 
electrotransport across the skin, a detailed 
evaluation of the relevant literature, and a 
perspective on the future, are presented.  
 
II. Mechanisms of transport 
during reverse iontophoresis 
A. Electromigration 
Conventionally, in iontophoresis, a 
constant current is applied, such that the flow 
of electrons is translated into an ion flux across 
the skin. A power supply establishes the 
electric field that causes electrons to migrate in 
the “electrical” portion of the circuit and ions 
to flow in the “ionic” part (Figure 1). It follows 
that the number of electrons flowing through 
the “electrical” portion of the circuit is exactly 
balanced by the amount of ionic charge 
flowing through the skin [3]. 
The electromigration contribution to 
iontophoretic transport is a direct result of 
current application. Ionic transport proceeds 
Figure 1: Reverse iontophoresis: a schematic diagram illustrating the experimental set-up. Constant
current is delivered to the anode and the cathode from a power supply. Cationic and neutral
substances are drawn towards the cathode by electromigration (2), electroosmosis (3) and (to a
negligible extent, typically) passive diffusion (1). Anionic compounds are attracted into the anode
chamber by electromigration (2), while convective solvent flow (3) opposes this phenomenon
(again, passive diffusion (1) is negligible). 
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through the skin to maintain electroneutrality 
[1,3,7]. Faraday's law applies to steady-state 
transport and relates the number of ions 
crossing the membrane to the electric current, 
the time of current passage and the charge per 
ion [1,3]:  
i
i
i zF
iTM
.
.=  Equation 1
where Mi is the number of moles of the ‘i’ ion, 
T is the time (s), zi is the valence, F is 
Faraday's constant (96 487 C.mol-1), and ii the 
current (A) carried by the ith species.  
Given that usually there is more than one 
ion moving across the barrier, the total number 
of moles transported (M) by the total current 
flowing (I) is given by:  
∑ ∑==
i i i
i
i z
i
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TMM  Equation 2
where ∑=
i
iiI  Equation 3
This leads to the concept of an ion 
transport number (efficiency of transport) 
which is the fraction of the total charge that it 
transports:  
I
i
t ii =  Equation 4
It follows that Equation 1 may be 
rewritten:  
i
i
i zF
TItM
.
..=  Equation 5
With respect to the subject of this review, 
the experimentally measured extraction flux 
(Ji, mol.s-1) is defined by the ratio of number of 
moles transported (Mi) to the sampling time 
(T) (i.e., the duration of reverse iontophoresis):  
I
zF
t
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==  Equation 6
Equation 5 shows that iontophoretic 
extraction is determined by the intensity of 
current, the time of iontophoresis, the charge 
and the transport number of the ion of interest. 
Current intensity (I) is directly and easily 
controlled by the power supply but is limited, 
for practical purposes in vivo, to no more than 
0.5mA/cm² [6]. The time of each extraction 
period must be sufficiently long to ensure that 
enough analyte is available for detection but 
not so long that clinically significant changes 
in the systemic concentration may have 
occurred. In any case, it must be recognized 
that reverse iontophoresis can only provide an 
estimation of the average level of the analyte in 
the body during the sampling period.  
The charge (zi) of the extracted ion is 
dictated by its molecular structure, and 
determines the polarity of the electrode at 
which sampling/analysis will be performed. 
The transport number, however, is difficult to 
estimate theoretically as it depends on the 
other ions contributing to the transport of 
charge across the skin. When an electric field 
is established across a membrane, ions on 
either side will migrate in the direction dictated 
by their charge. The speed of migration of an 
ion is determined by its physicochemical 
characteristics and the properties of the media 
through which the ion is moving [3,7,8,10]. 
The sum of the individual ionic charges 
flowing across the skin must equal the number 
of electrons “delivered” by the power supply; 
in other words, there is “competition” among 
all the ions present to carry the charge.  
The transport number of the ion of interest 
(the ith ion) may also be expressed as follows: 
∑
=
= n
j
jjj
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 Equation 7
where cj is the concentration (mol.cm-3), zj the 
valence, and uj the mobility (cm2.s-1.V-1) of 
each of the “n” ions in the system [7].  
Logically, the transport number depends on 
concentration (i.e., the available amount of a 
particular ion to participate in carrying charge 
across the skin). Likewise, it makes sense that 
ions, which are more mobile, will play a 
greater role in the movement of charge through 
the barrier. Note, however, that the relevant 
values of concentration (c) and mobility (u) are 
those inside the skin, rendering their estimation 
tricky at best and emphasizing the limitations 
of Equation 7 as a predictive tool. 
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In reverse iontophoresis, the concentration 
of the analyte is the variable of interest and 
will depend (in the case of a drug being 
monitored, for example) on the dosage 
regimen and the relevant pharmacokinetics. 
Furthermore, with respect to electromigration, 
only the ionized fraction of the analyte is 
extractable and this will depend on the relevant 
pKa. Similarly, for analytes that are bound to 
proteins, it is clear that only the free fraction 
can significantly contribute to charge transport 
across the skin. Figure 2 illustrates this point 
for phenytoin, a drug that is normally ~90% 
bound to albumin. As far as ionic mobility is 
concerned, regardless of the medium through 
which transport is occurring, an inverse 
dependence upon molecular size can be 
confirmed (and this is another reason, of 
course, why only unbound substances are 
extractable by reverse iontophoresis). In 
summary, therefore, it can be concluded that 
an ion can function as a major charge carrier if 
it is small, fully charged, at high concentration, 
and not significantly protein-bound. 
Additionally, and ideally, “competing” ions are 
minimized, a situation not practically 
realizable for reverse iontophoresis where the 
major charge carriers are Na+ and Cl-. 
Lastly, it is worth noting that the transport 
number is a “formulation-dependent” 
parameter applicable for a given set of 
conditions. The transport number ti can be 
determined experimentally; for example, by 
dividing the total amount of the ion transported 
by the total charge delivered (using Faraday's 
law, Equation 1), or from the gradient of a 
graph of ion flux versus current intensity (as in 
Equation 6) [11].  
 
B. Electroosmosis 
At physiologic pH, the skin is negatively-
charged and cation-permselective. When an 
electric field is imposed across this type of 
membrane, there is convective or 
electroosmotic solvent flow induced in the 
anode to the cathode direction (i.e., in the 
direction of counter-ion migration) [5,12]. This 
stream of solvent carries along with it 
dissolved solutes thereby enhancing the 
transport of neutral and, especially, polar 
molecules. Electroosmosis thus reinforces the 
transport of cations while acting against that of 
anions.  
Figure 2: In vitro reverse iontophoresis fluxes of phenytoin at the anode illustrate that only free
drug is extracted. The open bars (mean ± SD) indicate extraction of drug from a subdermal
compartment that did not contain albumin. The filled bars represent data obtained when human
serum albumin was present at 44 g/l. The results are consistent with a free fraction of phenytoin of
approximately 0.1. Data redrawn from [25]. 
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Important characteristics of this 
mechanism of electrotransport are, first, that 
the solvent volume flow (Jvs,          
volume.time-1.area-1) is proportional to the 
potential gradient across the skin [12,13] and, 
second, that the electroosmotic flux of solute 
(Ji) is independent of molecular size (at least as 
long as the solute diameter does not approach 
that of the transport pathway) [5,12]. The 
relationship between the molar flux (Ji) of the 
solute “i” and its molar concentration (ci) is 
given by [14]:  
iVSi cJJ .=  Equation 8
In an elegant series of experiments, Jvs 
during iontophoresis [14] was determined to be 
6-19 µl.h-1.mA-1.  
In addition to the current density, the pH 
and the ionic strength are electrode formulation 
parameters that may modulate electroosmosis 
[15]. Modifying the pH on either side of the 
skin can change the charge on the membrane 
and hence its permselectivity. Practically 
speaking, only the surface pH can be altered in 
vivo, of course. Figure 3 illustrates that 
cathodic extraction of phenylalanine is 
enhanced by as high a pH as can be feasibly 
maintained in contact with the skin surface 
[16]; in contrast, an acidic pH in the cathode 
chamber significantly impairs electroosmosis 
towards the electrode [15], while favoring 
extraction in the opposite direction, 
presumably due to a degree of neutralization of 
the fixed charge on the skin.  
For cathodal extraction, electroosmotic 
flow is increased by lowering the ionic 
strength of the electrode formulation [15,16]. 
This phenomenon is less obvious for anodal 
extraction [15]. However, it should be 
remembered that a finite level of electrolyte 
must be present in the electrode chambers 
(particularly at the anode) to support the 
Ag/AgCl electrochemistry. 
It has also been found that an anode 
formulation with CaCl2 or MgCl2, instead of 
NaCl, increased electroosmotic flow from 
beneath the skin surface towards the anode 
[17]. Shielding of the net negative charge on 
the skin is a possible mechanism for this 
observation. In contrast, in the cathode 
chamber, to which electroosmosis 
predominates, enhanced solvent flow was 
achieved by formulating the electrode bathing 
solution with Ca++ binding agents (calcein, 
heparin, or EDTA) presumably exposing a 
greater negative charge on the skin [16,17].  
Figure 3: Electroosmotic extraction of phenylalanine as a function of (a) the subdermal
concentration of the amino acid, and (b) the pH of the cathodal formulation. Reverse iontophoretic
fluxes increased linearly with analyte concentration, and were significantly higher at pH 8.5 than at
pH 7.4. Data redrawn from [16]. 
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C. The dominant mechanism: 
electromigration or 
electroosmosis?  
For small mobile ions, electromigration is 
clearly the principal mechanism; similarly, for 
neutral, polar substances, electroosmosis 
dominates as there is no electromigration 
possible from the electrode. Both mechanisms 
of electrotransport depend upon the applied 
current [10,18], with the effect being less 
marked for electroosmosis [13,19]. As the size 
of an ion increases, its mobility is reduced and 
electromigration is compromised. For cations, 
this means that the dominant mechanism 
switches from electromigration to 
electroosmosis with increasing molecular size 
[20]; for anions, on the other hand, the two 
contributions will ultimately self-cancel and no 
transport will be observed. A weak acid, 
therefore, which is only partially ionized at 
physiological pH, may be more easily 
extracted as its neutral form to the cathode 
(e.g. theophylline [21,22]). 
 
III. Advantages and 
limitations of reverse 
iontophoresis 
Noninvasive sampling methodologies are 
of obvious benefit to all patients for at least the 
following reasons: more information is 
obtainable as sampling can be performed more 
frequently, decreased pain and discomfort (i.e., 
better compliance), decreased risk of infection, 
potential for home-monitoring, etc.  
Furthermore, there are special populations 
for whom noninvasive diagnosis and 
monitoring would be particularly useful: 
patients who are repetitively subjected to 
invasive blood withdrawal procedures, patients 
who over- or under-respond to standard 
therapeutic regimens, subjects who are least 
able to tolerate, recognize or communicate 
problems with unexpected drug effects, and 
those who, for whatever reason, are either 
over- or under-dosed. Such patient populations 
include the “critically” ill under intensive care, 
cancer and AIDS sufferers, pregnant women, 
those displaying unusual pharmacokinetics, 
patients receiving simultaneous, multi-drug 
dosing regimens (e.g., the elderly) and, of 
obvious special concern, are pediatric patients, 
for whom the need for noninvasive diagnosis 
and monitoring is particularly acute.  
Even though reverse iontophoresis is much 
more efficient and reproducible than passive 
extraction, the quantities of analyte obtained at 
the skin surface are necessarily small. Dilution 
factors are likely to fall in the 10 to 100-fold 
range, or higher. Thus, analytical chemistry 
demands are significant and sampling periods 
may be so long, as a result, that changes in 
systemic concentration can occur. While this 
would be unacceptable in the case of glucose, 
for therapeutic drug monitoring at 'steady-state' 
the problem is less important (i.e., continuous 
monitoring is unnecessary, and a prolonged 
sampling time to obtain an average measure of 
concentration would be reasonable). Thus, an 
iontophoretic patch could be worn for a few 
hours at home, for example, and then sent to 
the clinical chemistry laboratory. Such an “off-
line” analysis and quantification would be 
acceptable, and a sampling device simpler and 
less expensive to design. 
An important limitation occurs when the 
skin accumulates the analyte of interest such 
that the initial extraction sample contains 
mostly information about this local 'reservoir' 
(this is the case for glucose [21] and lithium 
[23], for example). A “warm-up” period is 
necessary, therefore, before readings reflective 
of systemic levels are obtained. 
It is also true that the reverse iontophoretic 
flux does not reach a constant, 'steady-state' 
rate instantaneously [24,25] – the time to do so 
depends on the molecule of interest, and the 
dominant mechanism of electrotransport. 
However, whether this limitation is significant 
has not been completely established; for 
certain analytes, an acceptable correlation 
between extraction flux and subdermal 
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concentration is obtained prior to steady-state 
as well. 
An additional, and significant, limitation is 
that reverse iontophoresis will simply not work 
for molecules with particular physicochemical 
properties. Specifically, proteins, for example, 
are simply too large to be extracted in amounts 
that are quantifiable. Extremely lipophilic 
compounds, with extremely small aqueous 
solubilities, will also be undetectable; 
unfortunately, cholesterol falls into this 
category.  
 
IV. Case studies 
In 1954, reverse iontophoresis was first 
applied to the extraction of sodium and 
potassium ions [26]. Experiments were 
performed in vivo, in man, using a metal plate 
as the electrode. A current density of 0.5 
mA/cm² was applied over a skin surface of   
8.3 cm² for 5 minutes or longer. In a total of 
nearly 100 subjects, it was shown that age, 
gender, measurement time, measurement site 
and ambient temperature did not significantly 
affect the amounts of the cations extracted 
(Table 1). However, in the longer duration 
experiments, skin “damage” was observed due 
to the fact that the pH of the cathodal solution 
increased from between 6 and 7 to nearly 11. 
Clearly, therefore, electrolysis of water was 
taking place at the bare metal electrode and, as 
a result, it became sensible to henceforth use 
electrochemically reversible electrodes (e.g. 
Ag/AgCl) in iontophoresis studies [27]. 
The practical potential of reverse 
iontophoresis was appreciated much later (in 
1989) when it was demonstrated that the 
amount of a substance extracted across the skin 
in this way was linearly related to the 
subdermal (and, by extrapolation, the 
systemic) concentration [21]. This relationship 
was shown for clonidine, theophylline and 
glucose; that is, for a more or less fully 
charged cation, for a partially charged anion, 
and for a neutral polar molecule (Figure 4). 
 
Table 1: In vivo reverse iontophoretic extraction of potassium and sodium ions as a function of 
different parameters. The study group comprised 98 human volunteers. Data from [26]. 
 
 Potassium Sodium Ratio 
 (µmol/h) (µmol/h)  
    
Measurement time  
(10 measures) 1.8 ± 0.3 4.3 ± 0.5 2.4 ± 0.6 
    
Measurement site    
Volar surface forearm 1.8 ± 0.4 4.3 ± 0.8 2.4 ± 0.4 
Back of lower leg 1.6 ± 0.5 4.2 ± 0.8 2.7 ± 0.5 
Upper part of abdomen 1.9 ± 0.4 4.5 ± 1.0 2.4 ± 0.5 
    
Ambient temprature    
32-33°C 1.8 ± 0.3 4.3 ± 0.5 2.4 ± 0.4 
21°C 1.7 ± 0.4 4.4 ± 0.6 2.5 ± 0.4 
    
Gender    
Male 1.7 ± 0.5 4.3 ± 0.8 2.5 ± 0.3 
Female 1.7 ± 0.5 4.2 ± 0.6 2.5 ± 0.3 
    
Age    
<24 years 1.8 ± 0.5 4.2 ± 0.7 2.3 ± 0.5 
25-49 years 1.7 ± 0.3 4.3 ± 0.5 2.6 ± 0.3 
>50 years 1.6 ± 0.3 4.4 ± 0.5 2.7 ± 0.4 
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Subsequently, attention became focused 
upon glucose. Obviously, the availability of a 
noninvasive tool with which to monitor blood 
sugar in diabetics would be of immense 
medical benefit. The conventional, “finger-
stick” method, while precise and effective, is 
rarely used with sufficient frequency to reduce 
or avoid either hypo or hyper-glycemic events, 
despite compelling evidence that such an 
approach can significantly impact the chronic 
progression of the disease [28]. Reverse 
iontophoresis experiments in vitro [29] and 
initial in vivo studies in non-diabetic subjects 
[30] established proof-of-concept, and led to 
the commercial development of an integrated 
device (the Glucowatch Biographer® [31,32]) 
which is able to extract glucose 
iontophoretically across the skin and then 
assay sugar in situ with an on-board 
amperometric biosensor (Figure 5). The 
mechanism of electrotransport of glucose is 
electroosmosis, meaning that, during each 
Figure 4: In vitro iontophoretic sampling of clonidine, theophylline and glucose. The amounts of
the three compounds extracted across hairless mouse skin were linearly correlated with their
subdermal drug concentrations. Data redrawn from [21]. 
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sampling period (20 minutes, initially, a 
shorter time in the G2 version of the device), 
the amount of analyte to be detected is very 
small. An exquisitely sensitive analytical 
method is therefore required, and involves a 
highly optimized adaptation of the Pt-glucose 
oxidase sensor [33]. 
A significant quantity of data has now been 
published to illustrate the efficiency of this 
reverse iontophoresis technology to track 
changes in the blood sugar levels of diabetics 
over the entire range of glycemia [32,34-39]. 
The quality of this information led to the 
Glucowatch being approved for use in adults 
by the U.S. Food and Drug Administration in 
2001. Additional work in children (7-17 years) 
allowed this approval to be extended to 
juvenile diabetics the following year [40]. 
The long-term use and usefulness of the 
Glucowatch remain to be seen; nevertheless, 
there can be little doubt that this first truly 
noninvasive approach to the monitoring of 
blood sugar has made a paradigm shift in the 
field. It should be said that limitations of the 
approach are apparent, not least the lenghtly, 
2-3 hour, warm-up time before measurements 
can be made (due to the need to empty a 
glucose reservoir in the skin) and the fact that a 
“finger-stick” blood measurement is essential 
to calibrate the device. 
Other applications of reverse iontophoresis 
can be divided into diagnosis/monitoring and 
therapeutic drug monitoring. An innovative 
concept was to use the approach as a 
diagnostic tool for cutaneous inflammation 
[41]. Prostaglandin E2 (PGE2) was monitored 
in response to the transdermal delivery of 
irritant drugs. It was hypothesized and shown 
that low-level iontophoresis (0.05 mA/cm² 
over 2 cm²) of saline did not by itself provoke 
an increased production of inflammatory 
markers in vivo, in the hairless guinea pig. 
Subsequently, potentially irritant drugs 
(chlorpromazine, chloroquine, promazine, 
tetracaine and metoclopramide) were 
administered iontophoretically (Figure 6). 
Then, the anodal extraction of PGE2 from the 
site of drug administration was monitored and 
compared to the saline control. Significant 
increases were observed that correlated well 
with more classic determinations of irritation 
(e.g. the Draize test, lesion score). 
The reverse iontophoretic extraction of 
phenylalanine has also been demonstrated [16]. 
In phenylketonuria, a severe metabolic disease, 
the enzyme which biotransforms phenylalanine 
is missing. Early detection of the disease and 
subsequent control of the diet are therefore 
essential. Children with the disease are 
frequently monitored via blood samples and a 
noninvasive approach would therefore be of 
interest. Phenylalanine is zwitterionic at 
physiologic pH and is therefore extracted 
during reverse iontophoresis by an 
electroosmotic mechanism. Like glucose, it has 
been shown that the amounts detected at the 
Figure 6: Correlation between amount (in pg) of PGE2 recovered in the gel and irritation (r²=0.96).
Iontophoretic systems containing 100 mM drug were applied at 50 µA/cm² for 24h. Graph redrawn
from [41]. 
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cathode are proportional to the subdermal 
concentrations (Figure 3). However, 
phenylalanine systemic concentrations, even in 
phenylketonuria, are much less than typical 
glucose levels in diabetics. It follows that the 
analytical chemistry challenge for the 
monitoring of phenylalanine via reverse 
iontophoresis is considerable. On the other 
hand it should be said that continuous and 
frequent monitoring, as performed by the 
Glucowatch®, is not necessary for sufferers of 
phenylketonuria; a device that simply collects 
the sample (once a day or once a week, for 
example), which is subsequently sent for 
analysis at a central analytical laboratory, 
would be perfectly acceptable.  
Very recently, the reverse iontophoretic 
extraction of urea has been performed in 17 
patients (21-35 years) with impaired kidney 
function [42]. Urea was extracted by 
electroosmosis to the cathode by current 
application for 5 minutes. The extracted 
amounts correlated well with urea levels in the 
blood (r²=0.88). A logical application of this 
approach is to determine when dialysis should 
be performed in pediatric patients with kidney 
disease. A proof-of-concept study was 
subsequently conducted in six juvenile subjects 
(aged 9-16 years) for whom it was clearly 
shown that the amounts of urea extractable 
pre- and post-dialysis were quite different. 
Therapeutic drug monitoring applications 
of reverse iontophoresis have recently attracted 
heightened interest. The potential of the 
approach was first explored using caffeine and 
theophylline in a model designed to mimic the 
developing cutaneous barrier in a premature 
neonate [22]. While the idea appears feasible 
for full-term infants, whose stratum corneum 
performs as well as that of an adult, the 
technique is less satisfactory when the barrier 
is impaired (as is the case, of course, for 
premature babies). The problem is caused by 
the fact that, superimposed upon the 
electrotransport of the target analyte being 
extracted by reverse iontophoresis, there is a 
significant passive transport which confounds 
straightforward interpretation of the data. 
Nevertheless, the noninvasive nature of the 
technique implies that it may have other useful 
applications in the case of the sick neonate, at 
least when skin barrier function is intact. 
An important consideration when assessing 
the feasibility of reverse iontophoresis for 
therapeutic drug monitoring is the degree to 
which the compound of interest is protein-
bound. Logically, only the free drug is 
electrotransported across the skin as the 
protein-bound form is too large to be extracted. 
This issue has been addressed with two anti-
convulsant drugs, valproic acid [24] and 
phenytoin [25], approximately 90% of which 
are typically bound to plasma proteins. 
Reverse iontophoresis extraction of both drugs 
in a concentration dependent fashion was 
demonstrated over a wide-range encompassing 
those free levels observed in patients 
undergoing treatment. Valproate was extracted 
to the anode, while phenytoin (pKa=8.3) was 
recovered at both anode (the ionized fraction 
of the drug being attracted by electromigration) 
and cathode (the neutral form being carried by 
electroosmosis). When the level of protein was 
reduced in subdermal compartment, the 
amount of drug extracted was increased 
consistent with the rise of the free drug level 
(Figure 7). Equally, when monitoring 
phenytoin at a fixed subdermal protein level, 
introduction of valproate led logically to an 
increase in the free amount of the first drug 
and a higher rate of extraction due to the 
impact of competitive binding. The sensitivity 
of the method to respond to changes in free 
drug concentration in this way supports its 
potential usefulness for monitoring substances 
with a narrow therapeutic window. On the 
other hand, it must be recognized that, for 
lipophilic drugs like valproic acid and 
phenytoin, the free systemic concentrations are 
quite low (50 - 105 µM and 4 - 8 µM, 
respectively) and the amounts extracted by 
reverse iontophoresis are extremely small 
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(indeed, the in vitro experiments described 
above were performed with radiolabelled 
drugs). Once more, the analytical challenge in 
vivo will be very demanding. 
With lithium, a drug used to treat bipolar 
disorders, on the other hand, the analytical 
chemistry problem is much less severe. First of 
all, as a small, non-protein bound cation, Li+ is 
reverse iontophoretically extracted much more 
efficiently than the aforementioned anti-
convulsant drugs [43]. Second, the effective 
plasma concentrations are much higher for 
lithium such that the amounts detected at the 
skin surface can be assayed with existing 
technology. In vitro, the linearity and rapidity 
of Li+ extraction from a physiological buffer 
was simply demonstrated (Figure 8); when the 
concentration of Li+ in the sub-dermal 
compartment was varied over time, to simulate 
a pharmacokinetic profile, the extraction 
profile closely followed the “absorption” and 
“elimination” phases of the curve. 
Subsequently, an in vivo study [23] in patients 
being treated with lithium has shown the 
potential of reverse iontophoresis to provide a 
useful clinical tool. The reverse iontophoretic 
extraction fluxes were extremely well-
correlated with the corresponding plasma 
concentrations. 
 
Phenytoin 80 µM 40 to 80 µM 80 µM 
Albumin 44 to 22 g/l 44 g/l 44 g/l 
Valproate - - 0 to 542 µM 
Free phenytoin 8 to 16 µM 4 to 8 µM 9 to 14 µM 
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V. Optimization 
To expand the range of reverse 
iontophoresis applications, and improve on the 
existing technology, three strategies present 
themselves immediately for consideration.  
Most obviously, an improvement in 
analytical sensitivity is desirable. The lower 
the extracted amount that can be detected, the 
larger the number of potential candidates for 
the technique, and the shorter the time of 
sampling (and, hence, the lower the total 
charge passed across the skin). Further 
discussion of this point, however, is outside the 
scope of this review.  
Second, we may anticipate that 
optimization of the iontophoretic conditions 
will lead to maximization of the extracted 
amount. Thus, choosing the right current, 
current density, current profile and “acceptor” 
phase for the extracted analyte may be 
expected to improve the extraction efficiency. 
It is well-established that iontophoretic 
transport is directly proportional to the current 
and to the time of current application. In 
practice, however, there are limits to which 
these parameters can be increased. In terms of 
current density, it is generally agreed that 0.5 
mA/cm² is the maximum tolerable in man [6]. 
It follows that the total current can be 
increased by increasing the surface area 
extracted. But, if one maintains the current 
density fixed, even under these conditions, the 
degree of sensation experienced by the subject 
increases with treated area, presumably 
because a greater number of dermal 
nociceptors are activated [30]. There are at 
least two other difficulties associated with 
increasing the total current and the area of skin 
over which reverse iontophoresis extraction is 
performed: (i) more current means that the 
(typically) Ag/AgCl electrodes used must be 
coated with an augmented larger of AgCl to 
ensure that the correct electrochemistry 
operates throughout the sampling period, and 
(ii) more area implies a greater volume into 
which the sample is collected, and this may 
place more demands on the analytical method. 
While it has been suggested that iontophoresis-
induced reddening of skin can be reduced by 
‘pulsing’ the current on/off at different 
frequencies [15], the practical result is that the 
impact of irritation is not proven. In addition, 
as the extraction is much less efficient during 
the ‘off’ period, the total time for sampling has 
to be increased so that the total desired current 
can be passed. Alternating current shows no 
benefits whatsoever; however, switching 
electrode polarity at the end of each sampling 
period, as is done in the Glucowatch®, has the 
distinct advantage of allowing regeneration of 
the Ag/AgCl electrodes [44]. 
The third strategy is a method to avoid the 
present necessity to calibrate reverse 
iontophoretic extraction of an analyte with a 
blood sample. The amount of the compound of 
interest recovered at the skin surface is diluted 
in a certain volume of “acceptor” fluid. The 
concentration therein depends on the efficiency 
of extraction (the analyte’s transport number 
for an ion, the electroosmotic flow for a neutral 
species) and the volume of the “acceptor” 
solution. In the case of the Glucowatch®, for 
example, in each sampling period, the 
electroosmotic flow of less than 1µl is diluted 
into a volume of 400µl [44]; that is, a three 
order of magnitude dilution of the glucose. 
Calibration is therefore essential to relate the 
amount of sugar extracted to the blood 
concentration. The concept of an “internal 
standard” was initially proposed in 1993 [45] 
and has recently been significantly refined and 
reduced to practice [24]. The idea is as 
follows: reverse iontophoresis extracts 
numerous compounds at the same time; i.e., 
the process is non-specific and is only rendered 
specific for a particular compound by the use 
of a selective and precise assay. Suppose now 
that, in addition to the chosen target analyte 
(A), a second substance is also specifically 
analyzed in each sampling period. Suppose, 
further, that the blood concentration of this 
second molecule (IS) is effectively constant. It 
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follows that there should be a proportionality 
between the measured extraction flux ratio of 
A and IS (JA/JIS) and the ratio of their 
subdermal, or blood, concentrations (CA/CIS):  
IS
A
IS
A
C
CK
J
J .=  Equation 9
It follows that, given CIS is fixed and 
(presumably) known: 
IS
AIS
A J
J
K
CC .=  Equation 10
Thus, if the proportionality constant K can 
be determined and shown to be invariant in a 
subject population, then an experimental 
determination of JA/JIS, together with the 
known, ‘constant’ term (CIS/K), allows CA to 
be found without the need for blood sampling. 
The success of this idea rests on the 
independence of the iontophoretic transport of 
the analyte and the internal standard. In other 
words, it is important that a change in the 
transport number of A (due, for example, to a 
fall in its systemic concentration) is not 
compensated by an increase in that of IS. In 
this case, the validity of Equation 9 breaks 
down. When the concept was proposed 
initially [45], the design of the experiments led 
to exactly this violation, with the result that the 
method could not be validated. Recently, 
however, the principle has been re-visited [24], 
the experimental test designed more carefully, 
and the technique has been shown to work. 
The first demonstrated success involved the 
reverse iontophoretic extraction of valproate 
using glutamic acid as an anionic internal 
standard [24]. Although the concentration of 
glutamate in vivo is not sufficiently constant 
for this amino acid to be considered as a 
practical internal standard, it served perfectly 
to prove the concept in this study. It was 
shown that (i) the extraction flux of valproate 
varied linearly with its subdermal 
concentration, (ii) the extraction flux of 
glutamate remained constant as the valproate 
concentration fluctuated, and (iii) the ratio of 
the valproate to glutamate extraction fluxes 
was proportional both to their subdermal 
concentration ratio (Equation 9) and, as the 
glutamate concentration was fixed, to the 
valproate concentration. The approach allowed 
experimental variability to be reduced and 
permitted the subdermal valproate to be found 
even before the iontophoretic transport 
achieved ‘steady-state’. 
Subsequently, similar success was 
achieved with the Li+/Na+(analyte/internal 
standard) couple (Figure 9). The sodium ion is 
a useful and practical internal standard due to 
the fact that the concentration of NaCl in vivo 
does not vary outside the range of 125-145 
mM (and typically remains within a much 
narrower window); Na+ is also the major 
charge carrier in iontophoresis in the outward 
direction towards the cathode (much as Cl- 
performs the same function towards the 
anode). In vivo measurements, in patients, 
confirmed the constancy of the proportionality 
constant K in Equation 9. However, while in 
vitro experiments [46] indicated that Na+ may 
prove a valid internal standard for glucose as 
well, a subsequent in vivo study revealed that 
electroosmotic flow is a much more sensitive 
phenomenon and can vary by nearly a factor of 
ten even while the electromigrative flux of Na+ 
remains unchanged. It follows that it will be 
necessary to identify an electroosmotically-
extracted internal standard for glucose in order 
to avoid the need for blood sampling. 
 
VI. Conclusion 
Recent progress in reverse iontophoresis 
confirms its considerable potential. The 
approval and commercialization of the 
Glucowatch® represents an important 
milestone for the technology as the first truly 
noninvasive monitoring device for diabetics. 
The value of the method is readily appreciated, 
furthermore, not only as a research tool but 
also as a practical means by which to improve 
the quality of care (and life) in patient 
populations for which repetitive blood 
sampling represents a significant burden: 
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pediatric, geriatric and chronically ill 
individuals are obvious examples. Therapeutic 
drug monitoring is similarly accessible via 
reverse iontophoresis and it is to be hoped that 
the size of the commercial markets here 
(relative to that for glucose monitoring) do not 
deter the ultimate realization of practical 
devices. The future holds promise, in 
particular, if analytical tools continue to evolve 
in term of sensitivity, specificity, and 
miniaturization, as they have in the recent past. 
If this is the case, then the application of 
reverse iontophoresis in “smart”, feedback 
drug delivery systems, and in remote sensing, 
can be foreseen. 
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Résumé 
Buts : Cette étude évalue, in vitro, la capacité de l’ionophorèse inversée à constituer une méthode non-
invasive et alternative aux prises de sang pour le monitoring thérapeutique des médicaments fortement 
liés aux protéines plasmatiques. Ce travail démontre pour la phénytoïne, prise comme modèle, la 
relation de dépendance de l’extraction ionophorètique vis-à-vis des concentrations de phénytoïne (a) 
totale et (b) libre. Cette étude examine aussi l’aptitude de la technique (c) à suivre les effets d’une 
modification de la fixation protéique et (d) à devenir complètement non-invasive dès lors qu’un 
composé est utilisé comme standard interne pour sa calibration. 
Méthodes : Les expériences d’extraction ionophorètiques ont été conduites in vitro en utilisant une 
peau dermatomisée d’oreille de porc. La solution subdermique consiste en un tampon physiologique 
contenant des concentrations thérapeutiques de phénytoïne, d’un standard interne, de sérum albumine 
humaine et/ou d’acide valproique. 
Résultats : La forme ionisée de la phénytoïne fut extraite à l’anode par électromigration, tandis que la 
forme neutre fut extraite à la cathode par électroosmose. Une corrélation satisfaisante entre les 
quantités extraites de phénytoïne et les concentrations subdermiques fut observée. Il a été montré que 
l’extraction ionophorètique ne concernait que la fraction libre des concentrations subdermiques de 
phénytoïne et permettait de suivre les perturbations de l’équilibre de fixation protéique. L’acide 
acétique, introduit à concentration fixe dans le compartiment subdermique pour servir de « standard 
interne » fût extrait à l’anode. Il a été montré que le rapport des quantités extraites était proportionnel 
au rapport des concentrations subdermiques.  
Conclusions : Ces résultats démontrent que la surveillance thérapeutique de la phénytoïne par 
ionophorèse inversée est possible dans son principe. Cette technique est sensible aux changements de 
concentration du médicament sous la peau et fournit un accès spécifique à la fraction libre de 
phénytoïne. De plus, le contrôle simultané d’un second analyte (standard interne) dont l’extraction 
reste indépendante de celle de la phénytoïne, permet une calibration de la méthode. Cette approche 
rend la technique complètement non-invasive. Si pour le moment, la lente stabilisation de l’extraction 
ionophorètique exclue la possibilité de suivre un profil pharmacocinétique complet, cette limitation 
n’altère pas les bénéfices non-invasifs de la méthode pour proposer une valeur moyenne suffisante au 
contrôle périodique des taux de phénytoïne chez les patients. 
 
Mots clés : Ionophorèse, Transdermique, Monitoring thérapeutique, Phénytoïne 
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Non-invasive monitoring of phenytoin by reverse iontophoresis 
Benoît Leboulanger1,2, Richard H. Guy1,2 and M. Begoña Delgado-Charro1,2 
 
1 School of Pharmacy, University of Geneva, CH-1211 Geneva 4, Switzerland  
2 Centre international de recherche et d’enseignement, “Pharmapeptides”, F-74160 Archamps, France 
 
 
Abstract 
Transdermal iontophoresis offers a non-invasive sampling method for therapeutic drug monitoring. 
This study examined whether iontophoretic extraction (a) is concentration dependent, (b) reflects the 
subdermal level of unbound drug, (c) follows protein binding changes, and (d) becomes truly 
noninvasive when a co-extracted compound is used as an internal standard for calibration. 
Iontophoresis was conducted in vitro using dermatomed pig-ear skin. The subdermal solution was a 
buffer containing phenytoin at therapeutic concentrations, an internal standard at fixed level, human 
albumin and/or valproic acid. The ionized form of phenytoin was recovered at the anode by 
electromigration, while the neutral form was extracted to the cathode by electroosmosis. A satisfactory 
correlation between the reverse iontophoretic extracted amount of phenytoin and the subdermal 
concentration was observed. Iontophoresis extracted only the free fraction of phenytoin. At steady 
state, reverse iontophoresis monitored changes in free drug concentration provoked in the subdermal 
compartment. Acetate was introduced at a fixed concentration into the subdermal compartment to act 
as an “internal standard”. Subsequently, acetate and the ionized form of phenytoin were co-extracted 
to the anode. The ratio of the extracted amounts was proportional to the subdermal concentration ratio 
demonstrating a means by which the method may become truly non-invasive. 
 
Keywords: Iontophoresis, Transdermal, Drug Monitoring, Phenytoin
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I. Introduction 
Phenytoin is a drug of choice in the control 
of grand mal epilepsy (1). The therapeutic 
window of phenytoin, however, is narrow and 
demands particular care with respect to dose 
titration to ensure efficacy and to avoid 
undesirable side-effects (2). Consequently, 
therapeutic monitoring for phenytoin is 
necessary, particularly in children and in the 
elderly for whom wide inter-individual 
differences are seen (3;4). As is not unusual for 
drugs with a narrow therapeutic index, 
phenytoin is highly protein-bound in the 
plasma, with only the limited free fraction 
(~10%) able to distribute across biological 
barriers (5). Effective monitoring, therefore, 
must report on the unbound drug in the plasma 
(6;7). 
At present, the monitoring of phenytoin is 
performed via periodic blood sampling. 
Alternative, less invasive, approaches (for 
example, the measurement of drug levels in the 
sweat (8) or saliva (9;10)) have been 
investigated but have proven insufficiently 
reliable to be accepted in clinical practice (11). 
Clearly, a non-invasive method for sample 
collection, avoiding blood sampling, would be 
advantageous: the risk of infection for patient 
and health-care provider would be drastically 
reduced, and patient compliance would 
improve significantly making more frequent 
monitoring possible, even in an ambulatory 
setting. One might even envisage, in the long-
term, a self-monitoring device that would 
provide a patient with an alert should the 
detected drug level trend towards certain pre-
set limits. 
Reverse iontophoresis is a maturing 
technology that has the potential to offer these 
benefits. The method involves the application 
of a low current (<0.5 mA/cm2) to the skin so 
as to increase the percutaneous passage of ions 
and other compounds. Two mechanisms are 
implicated in iontophoresis: (i) 
electromigration, the direct interaction between 
the applied field and a charged ion, and (ii) 
electroosmosis, a convective solvent flow in 
the direction of anode to cathode, which results 
from the fact that the skin is net negatively-
charged at physiological pH. Thus, cations and 
neutral, polar species are extracted at the 
cathode by reverse iontophoresis, while 
anionic species can be sampled at the anode. 
The method has been shown capable of 
extracting a diverse range of compounds 
including various electrolytes and drugs (12-
14), glucose (15), phenylalanine (16) and urea 
(17). A commercial product for noninvasive 
glucose monitoring (the GlucoWatch 
Biographer®, Cygnus, Redwood City, CA), 
which is based on this technology, was 
approved by the U.S. Food & Drug 
Administration in 2001. 
A clear limitation of reverse iontophoresis, 
however, is the need to acquire a blood sample 
for calibration purposes. That is, the 
concentration of the analyte of interest in the 
electrode collection chamber is not identical to 
that in the blood, and can be significantly 
smaller. The dilution factor is difficult to 
predict because it depends not only on the 
known volume of the “acceptor” compartment, 
but also upon either the transport number of 
the analyte (i.e., the fraction of the total charge 
carried across the skin by an ion of interest) or 
the charge on the skin itself (which determines 
quantitatively the electroosmotic flow); neither 
of these parameters are routinely available 
meaning that the most direct solution to the 
problem is a blood sample with which to 
calibrate the efficiency of reverse iontophoretic 
extraction. This is exactly the approach used 
with the GlucoWatch®, for example. 
Recently, though, the use of a so-called 
“internal standard” calibration procedure has 
been proposed (13). The idea is that, in 
addition to the target analyte (A), a second 
compound (the “internal standard”, IS), which 
is nominally present at a fixed concentration 
subdermally, is also extracted and quantified. 
The ratio of the extraction fluxes (JA/JIS) 
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should reflect the ratio of their subdermal 
concentrations: 
JA/JIS = K . [A]/[IS] equation 1
If the proportionality constant (K) and [IS] 
are indeed constant, then the extraction flux 
ratio gives direct access to the subdermal 
concentration of A: 
[A] = (K# )-1. JA/JIS equation 2
where K# = K/[IS]. Here, acetate has been used 
as an internal standard with which to calibrate 
the anodal extraction of negatively-charged 
phenytoin (estimated to represent 
approximately 11% of the total amount present 
at pH 7.4). It is emphasized that acetate is used 
in this work as a model compound, in that its 
physiological concentration in vivo does vary 
over time. The unionized fraction of phenytoin 
was extracted to the cathode by 
electroosmosis; drug could therefore be 
quantified at both electrodes. 
The in vitro investigation comprised three 
specific aims: (i) to verify the linear 
dependence of phenytoin extraction on the 
subdermal concentration of the drug, (ii) to 
demonstrate that reverse iontophoresis reports 
on free drug levels in the subdermal 
compartment, and (iii) to validate the “internal 
standard” calibration concept. 
 
II. Methods 
A. Materials 
[4-14C]-5,5-diphenylhydantoin (phenytoin) 
and [3H]-acetate, sodium salt, were obtained 
from NEN™ Life Sciences Products, Inc. 
(Paris, France). Albumin (human fraction V), 
5,5-diphenylhydantoin (phenytoin), sodium 
salt, sodium acetate, sodium valproate, Tris, 
Tris HCl, Mops and NaCl were all purchased 
from Sigma-Aldrich (Saint Quentin Fallavier, 
France). Deionized water (resistivity ≥ 18.2 
MΩ.cm) was used to prepare all solutions. 
Porcine ears were obtained fresh from the 
local abattoir (Annecy, France) and were 
cleaned under cold running water. The whole 
skin was excised from the outer region of the 
ear, removing carefully any underlying tissue 
or cartilage. Typically, the full thickness 
membrane was dermatomed to about 750 µm 
before being cut into smaller squares, wrapped 
in parafilm® and stored at –20°C until used (a 
period no longer than two months, but usually 
much shorter). All transport experiments 
employed skin from different “donors” (n≥3). 
 
B. Iontophoresis 
(a) Apparatus: In vitro experiments used 
either vertical diffusion cells  (skin transport 
figure 1: Iontophoretic diffusion cells. The side-by-side, three compartment cell (left side), has an
effective skin surface area of 1 cm2; the subdermal volume is 3.5 mL, those of the electrode
chambers are 1.5 mL. The vertical cell (right side) (18) has an effective area of 0.8 cm2, a
subdermal volume of 6.5 mL, and the electrode chambers volume is 1 mL. Scale bar is 1 cm. 
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area = 0.78 cm2) (18), or a “side-by-side”, 
three-compartment cell (effective area = 1cm2) 
(figure 1). It was found that the “side-by-side” 
cells allowed easier and more rapid exchanges 
of the electrode chamber and subdermal 
compartment solutions. Iontophoresis at 
constant current was enabled via the 
connection of Ag/AgCl electrodes to an 
appropriate power supply  (KEPCO 1000M, 
Flushing, NY) (19). All iontophoresis 
experiments were performed in at least 
triplicate. 
(b) Phenytoin extraction as a function of 
concentration: Full-thickness skin was clamped 
in vertical diffusion cells and was equilibrated 
for 30 minutes in the presence of the following 
background, pH 7.4-buffered, electrolyte 
solution: anode - Tris/Tris HCl (90 mM Tris), 
cathode - 32 mM Tris + 34 mM Mops, 
subdermal compartment - 32 mM Tris + 34 
mM Mops + 133 mM NaCl. Then, the anode 
and cathode solutions were refreshed, while 
the subdermal chamber was replaced with the 
same buffer to which (a) phenytoin was added 
at one of the following concentrations: 4, 5, 8, 
10, 18 and 26 µM, and (b) acetic acid was 
introduced at 50 µM. To facilitate analysis of 
the subsequent extraction samples, the 
subdermal solution was “spiked” with 0.02 
µCi/mL of 3H-acetate and 0.3 µCi/mL of 14C-
phenytoin. At pH 7.4, phenytoin, which has a 
pKa of 8.3 (20), was calculated to be about 
11% ionized. Iontophoresis was performed in 
two steps: for 6 hours at 0.4 mA, followed by 
18 hours at 0.1 mA. At 3, 4, 5 and 6 hours 
post-initiation of iontophoresis, the current was 
stopped and the anode and cathode solutions 
were removed for analysis (of phenytoin and 
acetate) and replaced with fresh buffer. 
Equally, at the end of the 18-hour low-current 
step, anode and cathode solutions were taken 
for analysis. As a control, a passive diffusion 
experiment was also performed using the 
highest concentration of phenytoin. The 
electrode chambers, in this case, were sampled 
at 6 and 24 hours. 
(c) Extraction of free, unbound phenytoin: 
Dermatomed skin was clamped in “side-by-
side”, three-compartment diffusion cells and 
allowed to equilibrate as before for 30 minutes. 
The electrode chamber solutions were then 
refreshed and the subdermal (central) 
compartment was filled with the same buffer to 
which human serum albumin (HSA) and 
phenytoin had been added in amounts that 
provided a known concentration of free, 
unbound drug. Low-current iontophoresis (0.1 
mA) was then passed for 15h, at the end of 
which the electrode solutions were removed 
and replaced with fresh buffer. The current was 
then increased to 0.4 mA and drug extraction 
was determined by sampling the electrode 
chambers at 16, 17 and 18 hours post-initiation 
of iontophoresis. At 18 hours, in addition to 
replacing the electrode solutions with fresh 
buffer, the subdermal compartment was 
replaced with a new solution in which the free 
fraction of drug had been approximately 
doubled or halved. Current (0.4 mA) was re-
started for a further 4 hours and hourly 
sampling of the electrode solutions was again 
performed. The phenytoin unbound 
concentration was altered in one of three ways 
by: (a) maintaining the drug level fixed at 80 
µM and changing the HSA concentration from 
22 to 44 g.L-1 or vice versa; (b) changing the 
drug concentration from 80 µM to 40 µM or 
vice versa, while maintaining the level of HSA 
at 44 g.L-1; and (c) addition of 542 µM 
valproate, which competes with phenytoin 
binding to albumin, while maintaining 
phenytoin and HSA concentrations at 80 µM 
and 44 g.L-1, respectively. In all experiments, 
the subdermal solutions also contained 50 µM 
acetate (“spiked” with 0.02 µCi/mL of 3H-
Acetate) and 14C-phenytoin (0.45 µCi/mL). 
 
C. Determination of unbound 
phenytoin 
Equilibrium dialysis experiments (n≥3) 
were performed using regenerated cellulose 
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membranes (Spectra/Por® 6, molecular weight 
cut-off 2000, Spectrum® Laboratories, Inc., 
Rancho Dominguez, California, USA). The 
latter were conditioned in pH 7.4 buffer (32 
mM Tris + 34 mM Mops + 133 mM NaCl) for 
30 minutes and then clamped between the two 
halves of a conventional “side-by-side” 
diffusion cell (area = 1 cm2, volumes of 
“binding” solution and “dialyzed” solutions = 
3.5 mL and 1.5 mL, respectively). The two 
compartments were filled with fresh buffer and 
the cell was allowed to equilibrate for a further 
30 minutes. Subsequently, the cell was emptied 
and then refilled with 1.5 mL of buffer in the 
“dialyzed” compartment and 3.5 mL of the 
phenytoin/albumin or phenytoin/albumin/ 
valproate test solution in the “binding” 
compartment. The two compartments were 
magnetically stirred for 4 days at room 
temperature at the end of which 100 µL of 
each compartment was removed for analysis, 
and the extent of protein binding was 
calculated. 
 
D. Analysis 
All samples were mixed with 5 mL of 
scintillation cocktail (Ultima Gold XR, 
Packard Instruments SA, Rungis, France), and 
then analysed by for 14C-phenytoin and 3H-
acetate by liquid scintillation counting (LS 
6500, Beckman Instruments France SA, 
Gagny, France).  
 
E. Statistics 
Data analysis and linear regression were 
performed using Graph Pad Prism V.3.02. 
(Graph Pad Software, Inc. San Diego, 
California, USA). Linear regressions were 
always followed by the corresponding 
ANOVA. All the regressions reported in this 
work were significant (P<0.001). Paired t-tests 
were carried out with SigmaStatTM for 
Windows V.2.03 (SPSS Science Software 
Gmb, Erkrath, Germany); the significance 
level was fixed at P<0.01.  
 
III. Results and Discussion 
The passive extraction fluxes of phenytoin 
after 6 and 24 hours of diffusion were 0.1 ± 0.1 
pmol.cm-2.h-1 and 1.2 ± 0.9 pmol.cm-2.h-1, 
respectively, and were negligible in 
comparison to the iontophoretic values.  
The first objective of this study was to 
demonstrate proportionality between the 
reverse iontophoretic extraction flux of 
phenytoin and its subdermal concentration. 
Figure 2 demonstrates that this was indeed the 
case. Over a therapeutic range of subdermal 
levels, phenytoin extraction rates increased 
linearly. Extraction to both the anode and the 
cathode chambers was observed. 
Coincidentally, the electromigration transport 
of negatively-charged phenytoin (representing 
about 11% of that present at pH 7.4) to the 
anode was quantitatively quite similar to the 
figure 2: Iontophoretic extraction fluxes of phenytoin as a function of time and subdermal
concentration (A) at the anode, and (B) at the cathode. Each data point represents the mean ±
standard deviation (n=3). Lines of linear regression are drawn through the data. 
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electroosmotic transport of the uncharged drug 
(~89% of the total) to the cathode. It is worth 
noting that after 6 hours of reverse 
iontophoretic extraction, the amounts of 
phenytoin recovered at the skin surface were 
on the order of 300 times greater than the 
passive values. 
During the first 6 hours of the extraction 
experiment, the current was 0.4 mA. From 
figure 2, it is apparent that the efficiency of 
extraction was greater at 6 hours than at 5 
hours, suggesting that steady-state transport 
had not been attained. This conclusion is 
reinforced by the data at 24 hours, following 
iontophoresis at 0.1 mA for an 18-hour period: 
despite the lower current, during this time 
period, the extraction fluxes closely matched 
those seen at 6 hours. The linearity of the 
extraction process as a fraction of subdermal 
phenytoin concentration is summarized in  
table 1. 
The precise reason why the time to steady-
state is prolonged has not been unequivocally 
elucidated. Certainly, the lipophilicity of the 
drug plays a role. For example, like phenytoin, 
valproate requires several hours of constant 
current to achieve steady-sate extraction (13). 
On the other hand, a small cation, like lithium, 
reaches steady-state within an hour or less 
(14). Clearly, there are also endogenous ions 
within the skin at the moment that current 
passage is initiated. Due to their presence in 
situ, these species will of necessity contribute 
to carrying the charge at the beginning of an 
iontophoresis procedure. 
The efficiency and linearity of 
electroosmosis extraction (with respect to the 
subdermal drug concentration) are also 
demonstrated in figure 2 and table 1. The flux 
measured at 0.1 mA corresponds to a 
convective solvent flow of 1.6 ± 0.1       
µL.cm-2.h-1, a value in good agreement with 
that previously reported in the literature        
(2-6 µL.cm-2.h-1 at 0.2 mA) (21). Again, the 
table 1: Phenytoin extraction flux (J) is proportional to the subdermal drug concentration (C) (J = 
β.C + intercepta) at various times post-initiation of reverse iontophoresis.  
Electrode Time Current βb r2 
 (h) (mA) (µm/h)  
Anode 3 0.4 3 ± 1 0.63 
 4 0.4 5 ± 1 0.72 
 5 0.4 8 ± 1 0.75 
 6 0.4 11 ± 1 0.79 
 24 0.1 14 ± 1 0.90 
     
Cathode 3 0.4 4 ± 1 0.76 
 4 0.4 7 ± 1 0.80 
 5 0.4 11 ± 1 0.85 
 6 0.4 15 ± 2 0.86 
 24 0.1 14 ± 1 0.87 
aThe absolute value of the intercepts was 3.6 pmol.cm-2.h-1 or less 
bmean ± SD (n=3) 
 
table 2: Free fraction of phenytoin (α) determined by equilibrium dialysis. 
Phenytoin Albumin Valproate αa Free phenytoin nb 
(µM) (g.L-1) (µM)  (µM)  
80 44 - 0.11 ± 0.011 8.8 18 
40 44 - 0.11 ± 0.004 4.4 3 
80 22 - 0.21 ± 0.007 16.8 6 
80 44 542 0.19 ± 0.012 15.2 6 
amean ± SD 
bn=number of replicates 
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approach to steady-state is rather slow, and 
similar to that seen for electromigration 
towards the anode. 
From a practical standpoint, the need for 
steady-state is not necessarily essential. If 
subdermal levels are changing rapidly, then a 
long extraction period makes little sense. 
However, in the case of drugs like phenytoin 
(or valproate, or lithium), therapeutic 
monitoring is useful for checking and/or re-
setting steady-state plasma levels. The 
situation is not like glucose monitoring, for 
example, where frequent measurements must 
be made so that the sometimes rapid increases 
and decreases in blood sugar can be observed 
and acted upon as quickly as possible. 
The second goal of the investigation was to 
demonstrate that reverse iontophoresis 
extraction reflects the subdermal level of free 
drug. To prove this hypothesis, experiments 
were performed in which the unbound 
concentration of phenytoin was deliberately 
changed at a specific time. The reverse 
iontophoretic extraction before and after this 
change was then monitored. The free fraction 
of drugs was altered by (i) changing protein 
concentration while keeping the drug level 
constant, (ii) changing the drug concentration 
at fixed albumin level, and (iii) adding 
valproate, which competes with phenytoin for 
protein binding sites. 
The results of the equilibrium dialysis 
experiments, which were used to determine the 
unbound drug levels, are in table 2. It is first 
noted that the free fractions observed (~11%) 
are consistent with those reported in the 
literature for the “normal” range of phenytoin 
plasma concentrations (40-80 µM) (22-24). 
Second, as expected, a decrease in protein by a 
fraction of two induced a doubling of the 
amount of unbound drug (25). Third, the 
introduction of valproate led to a more than 
70% increase in free phenytoin; data in the 
literature support a similar phenomenon (with 
increases from 30% to 100% having been 
observed) (22). 
figure 3: Sum of anodal and cathodal reverse 
iontophoretic extraction fluxes of phenytoin 
(mean ± SD; n≥6) in response to changes in the 
free fraction of drug in the subdermal chamber. 
(A) Total [phenytoin] fixed at 80 µM; 
[albumin] changed from 44 to 22 g.L-1 (solid 
bars) or from 22 to 44 g.L-1 (open bars). (B) 
[albumin] fixed at 44 g.L-1; total [phenytoin] 
changed from 40 to 80 µM (solid bars) or from 
80 to 40 µM (open bars). (C) Total [phenytoin] 
and [albumin] fixed at 80 µM and 44 g.L-1; 
[valproate] changed from 0 to 542 µM. 
Changes described were made immediately 
after measurements taken at t=18 hours. The 
corresponding free fractions of phenytoin in 
these experiments are in table 2. 
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The reverse iontophoretic extraction fluxes 
of phenytoin were sensitive to these 
specifically induced changes in the free 
fraction of the drug (P<0.01, figure 3). The 
responses were essentially identical at the 
anode and cathode and figure 3 plots, 
therefore, the sum of the extraction fluxes of 
the charged and unionized drug. In these 
experiments, the extraction was monitored at 
16, 17 and 18 hours post-initiation of 
iontophoresis and the flux was shown to be 
constant. The changes were then provoked and 
the extraction rate of the drug was followed 
hourly for a further 4 hours. Figure 3A and 3B 
show that reverse iontophoresis detected 
correctly the increase and decrease in free 
phenytoin when either albumin concentration 
was decreased or increased, respectively, at 
fixed drug level, or when phenytoin 
concentration was increased or decreased at 
fixed protein level. Figure 3C shows that 
competitive protein binding by valproate 
(mimicking a not untypical situation in clinical 
practice) also elicited, as anticipated, a higher 
free fraction of phenytoin and a greater 
extraction flux. 
The third aim of this research was to 
examine whether the reverse iontophoretic 
sampling procedure may be performed without 
the need for a calibration blood sample. With 
this in mind, a second compound (acetate) at 
fixed concentration (50 µM) was introduced 
into the subdermal compartment with 
phenytoin, whose concentration was varied 
over a therapeutic range. The idea is that the 
measured extraction flux ratio 
(phenytoin/acetate) at the anode should be 
proportional to the corresponding ratio of their 
subdermal concentrations (equation 1). If the 
proportionality constant is indeed constant 
then, giving that the subdermal acetate level is 
fixed, measurement of the extraction flux ratio 
allows direct access to the “systemic” 
phenytoin concentration (equation 2).  
It was first necessary to show that the 
extraction flux of acetate remained constant 
while the subdermal concentration of 
phenytoin was allowed to vary. This was 
indeed the case as is illustrated in figure 4. As 
anticipated for the smaller, more water-soluble 
acetate ion, its extraction flux reached a 
steady-state flux rapidly (within 3 hours – see 
figure 5) and, when the current in this 
experiment was reduced from 0.4 to 0.1 mA 
 
figure 4: Simultaneous anodal extraction fluxes of phenytoin and acetate as a function of the 
subdermal phenytoin concentration; the subdermal concentration of acetate was fixed at 50 µM. 
Reverse iontophoretic extraction at 6 hours (current 0.4 mA) and at 24 hours (current 0.1 mA) is 
shown:       and      are the phenytoin and acetate fluxes, respectively, at 6 hours;       and      are the 
corresponding values at 24 hours. Each bar indicates the mean ± SD for at least 3 replicates 
experiments. 
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for the period from 6 to 24 hours, its transport 
fell by a factor of 4. 
The test of the “internal standard” 
hypothesis (equation 2) is presented in figure 
6. The values of K#, calculated using the 
extraction fluxes measured at 5, 6 and 24 hours 
were 0.5 ± 0.1, 0.7 ± 0.1 and 3.9 ± 0.3 mM-1, 
respectively (r2 values for the corresponding 
regressions were 0.76, 0.79 and 0.90). The fact 
that K# is not constant with time reflects the 
fact (as has already been pointed out) that 
phenytoin requires a considerably longer time 
to reach steady-state extraction than acetate. 
However, this does not necessarily invalidate 
the idea behind the “internal standard” 
hypothesis with respect to its practical 
application. Provided a specific time of 
extraction is selected, then the value of K# 
operative at that moment should then permit an 
estimate of the subdermal phenytoin 
concentration to be made. 
 
figure 5: Anodal, reverse iontophoretic extraction of acetate as a function of time and applied
current. Each data point is the mean ± SD of 6 replicates. The error on the value at 24 hours is
smaller than the size of symbol and cannot be visualized. 
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figure 6: The ratio of the anodal phenytoin and acetate fluxes plotted as a function of subdermal
phenytoin concentration after 5, 6 and 24 hours of iontophoresis. The results conform well to
equation 2, providing support for the “internal standard” concept. Each point represents the mean ±
SD of at least 3 replicates. 
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IV. Conclusion 
In conclusion, the results presented in this 
paper demonstrate, in principle, that 
transdermal therapeutic monitoring of 
phenytoin by reverse iontophoresis is possible. 
The sampling procedure is sensitive to changes 
in the drug’s concentration beneath the skin 
and provides access, specifically, to the free 
fraction of phenytoin that is not protein-bound. 
Furthermore, the simultaneous sampling of a 
second analyte, whose concentration remains 
constant relative to the variation in phenytoin 
levels, permits an “internal standard” 
calibration such that the approach is rendered 
completely non-invasive. However, the 
lipophilicity of phenytoin is such that its 
reverse iontophoretic extraction attains a 
steady-state rate only slowly. While this may 
not detract from the usefulness of the method 
to provide a simple means to monitor drug 
levels periodically in patients receiving chronic 
phenytoin therapy, this limitation does, for the 
moment, exclude the possibility of tracking a 
complete pharmacokinetic profile subsequent 
(for example) to a single oral dose. 
 
Abbreviations 
J: Extraction flux (units: pmol.cm-2.h-1) 
K: Proportionality constant (units: µm/h) 
between extraction flux (Jphenytoin) and 
subdermal phenytoin concentration. 
K#: Proportionality constant (units: mM-1) 
between ratio of extraction fluxes 
(Jphenytoin/Jacetate) and subdermal phenytoin 
concentration. 
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Résumé 
Buts : Cette étude évalue le potentiel de l’ionophorèse inversée à être proposée comme un outil 
alternatif et non-invasif dans la surveillance thérapeutique des médicaments et dans la réalisation des 
études pharmacocinétiques. Le lithium, nécessitant une surveillance et un contrôle fréquent fut choisi 
comme molécule modèle. Les objectifs étaient de (a) démontrer la relation linéaire existant entre 
l’extraction ionophorètique et les concentrations subdermiques, (b) d’examiner la capacité de 
l’ionophorèse à suivre des variations brusques de concentration subdermique, (c) d’évaluer le potentiel 
de l’ionophorèse comme outil dans les études de pharmacocinétique et (d) d’examiner la validité de la 
calibration de la méthode par un standard interne dans le but de rendre cette méthode complètement 
non-invasive. 
Méthodes : L’extraction transdermique a été menée in vitro en utilisant de la peau dermatomisée 
d’oreille de porc. La solution subdermique consistait en un tampon physiologique contenant des 
concentrations de lithium en rapport avec sa marge thérapeutique ainsi que deux standards internes : le 
sodium et le potassium à concentrations physiologiques fixes. La concentration de lithium dans le 
compartiment subdermique a été modifiée de deux manières : soit brusquement, soit en simulant des 
profils monocompartimentaux. 
Résultats : Le lithium a été extrait à la cathode par électromigration. Une bonne corrélation entre les 
concentrations subdermiques et les quantités extraites a été observée. L’ionophorèse inversée a 
démontré sa capacité à suivre des modifications brusques de concentrations subdermiques et des 
profils pharmacocinétiques. Il a été montré que les paramètres pharmacocinétiques (comme la 
constante d’élimination) peuvent être directement, et de manière non-invasive, estimés par cette 
méthode de monitoring. 
Conclusions : Cette étude confirme le potentiel de l’ionophorèse inversée à proposer une méthode 
alternative aux prélèvements sanguins pour le monitoring thérapeutique du lithium et la réalisation 
d’études pharmacocinétiques de manière complètement non-invasive. 
 
Mots clés : Ionophorèse, Ionophorèse inversée, Monitoring thérapeutique, Lithium, Extraction 
transdermique 
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Abstract 
Purpose: Transdermal iontophoresis was investigated as a non-invasive tool for drug monitoring and 
pharmacokinetic profiling. Lithium, a frequently monitored drug, was used as a model. The objectives 
were: (a) to demonstrate the linear dependence of the iontophoretic extraction flux of lithium on the 
subdermal concentration of the drug, (b) to evaluate the capacity of iontophoresis to monitor sudden 
changes in the subdermal level, (c) to investigate the utility of reverse iontophoresis as a tool in 
pharmacokinetic studies, and (d) to examine the validity of an internal standard calibration procedure 
to render the method completely non-invasive. 
Methods: Transdermal, iontophoretic extraction was performed in vitro using dermatomed pig-ear 
skin. The subdermal solution consisted of a physiological buffer containing lithium chloride at 
concentrations in the therapeutic range and two putative internal standards, sodium and potassium, at 
fixed physiological levels. The subdermal concentration of lithium was changed either in a stepwise 
fashion or by simulating one of two pharmacokinetic profiles.  
Results: Lithium was extracted via electromigration to the cathode. A excellent correlation between 
subdermal lithium concentration and iontophoretic extraction flux was observed. Iontophoresis tracked 
sudden concentration changes and followed kinetic profiles. In addition, the effective elimination rate 
constant could be directly, and non-invasively, estimated from the extraction flux data.  
Conclusions: Reverse iontophoresis is a potentially useful and non-invasive tool for lithium 
monitoring. 
 
Keywords: Iontophoresis, Reverse iontophoresis, Therapeutic drug monitoring, Lithium, Transdermal 
extraction 
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I. Introduction 
Currently, therapeutic drug monitoring and 
pharmacokinetic studies depend principally 
upon the quantification of the molecule in one 
or more blood samples. The invasive nature of 
the procedure, the associated risks of infection, 
the need for trained personnel and, for some 
populations (e.g., neonates), the technical 
difficulty, limit the frequency and complexity 
of these studies. As a result, drug kinetics in 
certain patient groups are poorly understood 
and drug monitoring, in general, is performed 
much less often than it should.  
There is a clear need, therefore, for the 
development of non-invasive techniques, 
which would be much better accepted by the 
patient and would offer the possibility of 
frequent and ambulatory self-monitoring (1, 2). 
Paediatric, neonatal, and geriatric patients, as 
well as the chronically and critically ill, would 
benefit most from the availability of such tools. 
For example, manic-depressive patients 
receiving chronic lithium therapy would profit 
from frequent monitoring that does not demand 
repeated visits to the hospital. These patients 
are carefully supervised because of (a) the 
wide inter-subject variability observed in dose 
requirement and tolerance to the drug, (b) the 
very narrow therapeutic index, and (c) a half-
life, which depends on kidney function, 
sodium intake and age (3). Monitoring is 
initially performed to adjust the dose; daily, 
weekly and, finally, monthly evaluations are 
carried out during the first 6 months. 
Thereafter, lithium levels are checked at least 
every three months to detect drifts in 
concentration (4). The latter may be due to age, 
pregnancy, low salt diet, fever, infection, drug 
interactions, other medical problems, and/or 
poor compliance with the dosage regimen (4-
6). At present, lithium monitoring requires 
blood sampling. Attempts to use either saliva 
or urine as alternative matrices have not been 
successful (3, 7-9).  
Reverse, transdermal iontophoresis has 
been proposed as an alternative technique for 
non-invasive monitoring (10-15). Potential 
applications in clinical chemistry and 
therapeutic drug monitoring have been 
identified. Iontophoresis involves the 
application of a small electrical current (<0.5 
mA/cm²) to the skin (16, 17), and results in 
enhanced transport across the membrane via 
two possible mechanisms (18-20).  The first, 
electromigration, only concerns ions, which 
carry the current through the skin towards the 
electrode of opposite polarity.  Thus, in reverse 
iontophoresis, anions are extracted at the anode 
and cations (such as lithium) at the cathode 
(negative electrode). The ion flux is related to 
the intensity of current applied via equation 1:  
.FZ
I.tJ
a
a
a =   Equation 1
where, Ja, ta and za are the flux, transport 
number and valence, respectively, of the ion 
“a”; I is the intensity of current applied, and F 
is Faraday's constant. It has been shown that, 
in the presence of competing ions, the transport 
number (i.e., the percentage of the charge 
carried) of a given ion is proportionally related 
to its concentration in the donor solution (21).  
Thus, in reverse iontophoresis, it is expected 
that the flux of a given analyte should be 
related to its concentration in the subdermal 
fluid.  The second mechanism of transport is 
electroosmosis, which is a convective solvent 
flow, in the anode-to-cathode direction, due to 
the fact that the skin has a net negative charge. 
This flow increases the transdermal transport 
of neutral (e.g., glucose) and zwitterionic 
species and supplements the electromigration 
of cations.  It has also been shown that the 
electroosmotic transport of an analyte is 
directly proportional to the concentration of the 
species present in the solvent (19, 22). 
The Glucowatch Biographer® (Cygnus, 
Inc., California, USA), which monitors blood 
sugar, is the only approved reverse 
iontophoretic system on the market (23). 
Before use, the device has to be calibrated via 
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a conventional finger-stick so that the amount 
of electroosmotically-extracted glucose 
(measured in situ by the appparatus), in a 
defined period of current passage, can be 
related to the corresponding blood level. At 
present, it is unknown whether iontophoretic 
devices relying on electromigrative extraction 
will also require a similar calibration; such 
would be the case, for example, if the transport 
number of a specific ion demonstrated a 
significant inter-individual variability in vivo.   
In any case, the development of a non-
invasive calibration procedure can clearly be 
identified as a sensible priority for future 
applications of reverse iontophoresis in drug 
monitoring and, recently, the use of an 
“internal standard” approach has been 
proposed (10, 11, 24).  The procedure takes 
advantage of the fact that iontophoretic 
extraction is not specific.  For example, in the 
case of lithium, several other cations will be 
simultaneously extracted at the cathode.  If one 
of these ions, which may be referred to as the 
“internal standard”, is present in the body at a 
relatively constant concentration, then its 
iontophoretic flux (JI.S.) would be expected to 
be constant as well.  It follows that the ratio of 
the extraction fluxes, JLi/JI.S. should be directly 
proportional to the ratio of their respective 
concentrations (CLi/CI.S.) (10, 11, 24). Given 
that CI.S. is constant, JLi/JI.S becomes directly 
proportional to CLi:  
JLi/JI.S. = RI.S. = γ#. CLi Equation 2
 
where γ# is a constant. This hypothesis is tested 
here using sodium and potassium as candidate 
internal standards for lithium.  
In summary, this work explores the 
potential of reverse iontophoresis as a non-
invasive procedure for lithium monitoring and 
for pharmacokinetic profiling.  In particular, 
the following questions have been addressed: 
(i) Are iontophoretic extraction fluxes of 
lithium proportional to the corresponding 
subdermal concentrations? (ii) Is iontophoresis 
capable of following sudden changes in the 
lithium subdermal concentration? (iii) To what 
extent may reverse iontophoresis be useful for 
pharmacokinetic studies? (iv) Does the 
"internal standard" calibration approach work? 
 
II. Materials and methods 
A. Materials 
8 M LiCl solution, NaCl, KCl, NaOH, 
KOH, Hepes, Tris, TrisHCl, Mops, Ag wire 
99.9%, AgCl 99%, Pt 99.9% were purchased 
from Sigma-Aldrich (Saint Quentin Fallavier, 
France). Deionized water (resistivity ≥ 18.2 
MΩ.cm) was used to prepare all solutions. 
 
B. Skin preparation 
Porcine ears were obtained fresh from the 
local slaughterhouse (S.O.D.E.X.A., Annecy, 
France) and were cleaned under cold running 
water. The whole skin was removed carefully 
from the outer region of the ear and separated 
from the underlying cartilage with a scalpel. 
Both full thickness and dermatomed         
(~750 µm) skin were used. The skin was 
wrapped individually in Parafilm® and 
maintained at –20°C for no longer than two 
months. All experiments were performed with 
3 to 6 replicates, using skin samples 
originating from different pigs. 
 
C. Equipment 
Two types of iontophoretic cells were 
used: (a) vertical iontophoretic cells (25) with 
an effective transport area of 0.78 cm², a       
6.5 ml subdermal volume and 1 ml electrode 
chambers; and (b) side-by-side three-
compartment cells (11) with a 1 cm2 skin 
surface area, a 4.54 ± 0.15 ml subdermal 
compartment and 1.5 ml electrode chambers. 
Access ports to the subdermal compartment 
permitted the lithium concentration to be 
perfused at a fixed level, to be changed 
abruptly, and to be modulated continuously 
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over time so as to mimic a pharmacokinetic 
profile. A manual power supply (either a 
KEPCO 1000M, Flushing, NY, USA or a 
Yokogawa 7651, Tokyo, Japan) was used to 
deliver a constant current via Ag/AgCl 
electrodes (26).  
 
D. Fixed-concentration extraction 
experiments 
Full-thickness skin was clamped in vertical 
iontophoretic cells. First, the subdermal and 
anodal compartments were filled with a pH 7.4 
buffer comprising 25 mM Hepes and 133 mM 
NaCl.  The cathodal compartment was filled 
with a pH 7.4 buffer comprising 25 mM Hepes 
and 10 mM KCl.  
After 30 minutes equilibration, the anodal 
and cathodal solutions were refreshed.  The 
subdermal chamber was filled with the “donor” 
solution, which consisted of the same buffer to 
which lithium chloride was added at one of 
three different concentrations (0.6, 1.0 and 1.5 
mM) corresponding to the drug's therapeutic 
range.  Iontophoresis was performed for 5 
hours by applying a constant current of 0.4 mA 
via Ag/AgCl electrodes. The current was 
stopped hourly to permit the collection and 
replacement of the entire electrode chambers 
solutions. Three replicates were made. The 
samples were assayed for lithium by graphite 
furnace atomic spectrometry (GFAS).  
 
E. Stepwise concentration 
change experiments 
Dermatomed skin was clamped between 
the three compartments of side-by-side cells. 
During a 30-minute equilibration period, the 
subdermal compartment was filled with 3.5 ml 
of a pH 7.4 buffer solution containing 32 mM 
Tris, 34 mM Mops and 133 mM NaCl. The 
anodal chamber was filled with a pH 7.4 buffer 
comprising 90 mM Tris/Tris HCl, while the 
cathodal chamber was also buffered at 
physiological pH with 32 mM Tris and 34 mM 
Mops.  Subsequently, the anodal and cathodal 
solutions were refreshed. The subdermal 
chamber was filled with the same buffer to 
which 4 mM potassium chloride and lithium 
chloride at either 0.95 mM (first experiment) 
or 1.7 mM (second experiment) were added. 
The concentration of LiCl in the subdermal 
donor solution was then changed in a stepwise 
fashion at 120 and 210 minutes: in the first 
experiment, to 2.7 mM and 1.8 mM, 
respectively; in the second, to 0.6 and 1.1 mM. 
Iontophoresis was performed for 5 hours at 
a constant current of 0.4 mA.  Six replicates 
were carried out.  Every 30 minutes, the 
current was stopped and the entire electrode 
chamber solutions were sampled and refilled 
with fresh buffer. The samples were assayed 
for lithium by graphite furnace atomic 
spectrometry (GFAS) and for potassium and 
sodium by flame atomic absorption 
spectrometry (FAAS). 
 
F. Concentration-profile kinetic 
experiments 
Dermatomed skin was clamped in side-by-
side cells. After an equilibration period as 
described before, the solutions in the three 
compartments were refreshed.  Then, the 
lithium content of the subdermal solution was 
varied to simulate the plasma concentration 
profile observed after either an IV bolus or a 
continuous infusion (see below). Iontophoresis 
was performed at a constant current of 0.4 mA 
for 5 hours. Every 30 minutes, the current was 
stopped (for a period of ~5 minutes) to permit 
the collection and the replacement of the entire 
electrode solutions. At the midpoint of each of 
iontophoretic period, 10 µl of the subdermal 
solution were sampled and the actual 
concentrations of lithium, sodium and 
potassium therein were quantified by ionic 
chromatography with conductimetric detection, 
allowing their iontophoretic extraction fluxes 
to be calculated.  
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Intravenous bolus: A syringe pump   
(Genie 8, Kent Scientific Corporation, 
Torrington CT, USA) infused the subdermal 
buffer (pH 7.4, 32 mM Tris, 34 mM Mops,  
133 mM NaCl, 4 mM KCl) at a rate of 1 ml/h. 
After one hour of iontophoresis, 6.2 µl of a   
0.8 M aqueous solution of LiCl were directly 
added via a bolus injection into the subdermal 
compartment of each cell. 
Constant rate infusion: A syringe pump 
infused the subdermal buffer as before, but at a 
rate of 4 ml/h. After one hour of iontophoresis, 
the composition of the infused solution was 
modified to incorporate 1.4 mM LiCl. 
 
G. Analytical techniques 
Graphite furnace atomic absorption 
spectrometry with Zeeman effect quantified 
lithium at 670.8 nm (Perkin Elmer 4100 ZL, 
Norwalk, CT, USA). The samples were diluted 
20-fold in 0.2% HNO3 before injection. 
Flame atomic absorption spectrometry 
(Perkin Elmer  AA Analyst 300, Perkin-Elmer 
Corporation, Norwalk, CT, USA) was used to 
measure sodium and potassium concentrations 
in iontophoretic and donor samples.  The ions 
were quantified at 589.1 nm and  769.9 nm, 
respectively, after a 10-fold dilution of the 
samples in 10% HNO3. 
Ionic chromatography was used to quantify 
lithium, sodium and potassium. The Dionex 
DX-600 system (Voisins le Bretonneux, 
France) was equipped with a GP-50 pump, and 
an AS-50 thermal compartment (25°C).          
A 6 mM H2SO4 mobile phase was pumped     
(1 ml/min) through a CS-16 cationic column. 
Detection involved a ED-50 detector and an 
Atlas suppressor (61 mA) . 
 
H. Statistics 
Data analysis, linear and non-linear 
regressions were performed with Graph Pad 
Prism V.4.0 (GraphPad Software Inc. San 
Diego, USA). All linear regressions shown in 
this work were significant (p<0.001). The data 
from each iontophoresis cell was individually 
fitted to the corresponding regression equation, 
and the “kinetic” values derived correspond to 
the average and standard deviation (SD) of 6 
cells.  Kruskal-Wallis and repeated measures 
ANOVA analysis were performed with 
SigmaStat V.2.03 (SPSS Science Software 
GmbH, Erkrath, Germany). The statistical 
significance level was fixed at P<0.05. 
(AUC)0→t was determined via the trapezoidal 
method (Prism V.4.); (AUC)t→∞ was calculated 
from the ratio of the last value measured to the 
elimination constant rate (27). 
 
III. Results and discussion 
A. Fixed-concentration extraction 
experiments 
The objective of this first set of 
experiments was to verify the concentration 
dependence of the lithium iontophoretic 
extraction flux over the therapeutic range.  
Lithium, a positive ion, was extracted at the 
cathode (negative electrode) as expected.  
Figure 1 shows that lithium flux stabilized 
after approximately 2-3 hours of iontophoresis.  
This behaviour has been previously observed.  
The delay results from the fact that, when the 
current is started, the most readily available 
charge carriers are the endogenous ions already 
present inside the skin (18); only after this 
“reservoir” is depleted can lithium assume its 
full role in transporting charge across the 
barrier.  Lithium transport became steady after 
a few hours of iontophoresis, in a similar 
manner to that reported for acetate, but more 
rapidly than has been observed for valproate 
(~5 hours) (10) and phenytoin (>10 hours) 
(11). The iontophoretic lithium flux, when the 
“donor” concentration was 0.6 mM, reached 
20.0 ± 1.0 nmol.h-1 a value nearly an order of 
magnitude greater than that found for valproate 
(2.3 nmol.h-1) under similar conditions (10). 
This illustrates the critical role of the 
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physicochemical properties (molecular weight, 
mobility and polarity) of the analyte of interest 
in determining the feasibility of iontophoretic 
extraction. Lithium, being smaller, more 
mobile and much less lipophilic than valproate, 
competes much better in carrying the charge 
across the skin. Furthermore, electroosmosis 
assists lithium transport while reducing that of 
the anionic valproate (19). 
The relationship between lithium flux and 
subdermal concentration was analyzed by 
linear regression (Equation 3), and the results 
are in Table I:   
JLi = γ. CLi Equation 3
 
The values of the slope (γ) progressively 
increased until the third hour of extraction.  
Satisfactory correlation coefficients were 
observed as early as 2 hours after the initiation 
of iontophoresis (r² = 0.85), with the best 
correlation obtained at 5 hours (r² = 0.97).  
Overall, this first experiment demonstrated that 
a linear relation between lithium extraction 
flux and the subdermal concentration of the 
drug is established after a relatively short 
sampling time.  
 
B. Stepwise concentration 
change experiments 
The objective here was to investigate 
whether the iontophoretic extraction procedure 
could follow abrupt subdermal concentration 
changes.  The experiments began with an 
initial 2-hour period of current passage during 
which the lithium subdermal concentration was 
maintained constant at either 0.95 mM or     
1.7 mM (Figures 2 (a) and (b), respectively).  
During this time, the iontophoretic fluxes 
increased and reached steady values faster than 
observed before. This was probably due to the 
smaller thickness of the skin membrane used 
Table I: Linear regressions of the iontophoretic extraction fluxes of lithium (JLi in units of nmol/h) 
as a function of the drug's subdermal concentration (CLi in mM) after different times of 
iontophoresis (data in Figure 1), according to the equation: JLi = γ· CLi + Intercepta. 
 
Time  γ r² 
(h)  (µl/h)  
1  13 ± 6 0.43 
2  31 ± 5 0.85 
3  42 ± 6 0.89 
4  44 ± 7 0.87 
5  43 ± 3 0.97 
a The absolute values of the intercepts were 9 nmol/h or less 
 
 
0 1 2 3 4 5 6
0
20
40
60
80
CLi=1.5 mM
CLi=1.0 mM
CLi=0.6 mM
Time (hour)
J L
i (
nm
ol
/h
)
 
Figure 1: Reverse iontophoretic extraction fluxes of lithium as a function of time and subdermal
lithium concentration.  Each data point represents the mean ± standard deviation (n=3). 
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(dermatomed versus full-thickness tissue) and 
the shorter sampling intervals employed       
(30 minutes versus 1 hour), which allowed the 
kinetics to be determined more precisely.  
The concentration of LiCl in the subdermal 
donor solution was then changed in a stepwise 
fashion at 120 and 210 minutes: in the first 
experiment, to 2.7 mM and 1.8 mM, 
respectively (Figure 2 (a)); in the second, to 
0.6 and 1.1 mM (Figure 2 (b)).  These sudden 
changes, which are much more abrupt than any 
possible in an in vivo situation of course, were 
carried out to test the responsiveness of reverse 
iontophoresis to such variations. 
Figure 2 shows that iontophoresis was 
quite efficient in following the stepwise 
changes in the subdermal composition.  
Lithium fluxes responded appropriately to the 
new conditions established in each case and 
reached new steady values after a relatively 
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Figure 2: Monitoring of lithium subdermal concentration changes: (a) first experiment, (b) second
experiment. The continuous lines indicate the stepwise changes in the subdermal lithium
concentrations. The open squares are the lithium iontophoretic fluxes. Each data point represents
the mean ± standard deviation (n=6).  Transport numbers of lithium (tLi, open bars) potassium (tK,
solid bars) and sodium (tNa, hatched bars) determined from the iontophoretic fluxes in (c) the first
experiment, and (d) the second experiment.  Linear regressions between the ratio of extraction
fluxes (RNa) and either the lithium subdermal concentration or the ratio of subdermal
concentrations (CLi/CNa) determined using the data from (e) the first experiment, and (f) the second
experiment.   
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short delay.  As the “physiological” buffer 
used remained constant, increasing or 
decreasing the lithium concentration conferred, 
respectively, a better or worse chance for the 
drug to compete to carry the charge across the 
skin (i.e. to adopt a higher or smaller transport 
number (18)).  
Taken together, the first two sets of 
experiments confirm that reverse iontophoresis 
of a highly mobile drug, such as lithium, can 
provide credible information about 
concentration changes occurring in the internal 
medium with a relatively short time-lag.  It 
should be emphasized that such delays seen 
under in vitro conditions may not be observed 
in vivo, where the rich dermal vasculature is 
intact.  By way of example, attention may be 
drawn to the fact that the GlucoWatch 
Biographer®, after its initial warm-up period, 
provides a measure of blood glucose every    
10 minutes (23). 
 
Internal standard calibration 
As discussed before, the use of 
iontophoresis in glucose monitoring requires 
an initial calibration to be performed via a 
conventional (“finger-stick”) blood 
measurement.  Clearly, in situations for which 
less frequent monitoring is necessary, an 
alternative, noninvasive calibration procedure 
is essential.  We have, therefore, considered 
the use of an internal standard calibration 
(Equation 2) (10). Endogenous electrolytes, 
such as sodium and potassium, seemed, a 
priori, good candidates as internal standards 
for lithium reverse iontophoresis.  First, these 
are cations, extracted at the cathode and, like 
lithium, principally by electromigration.  
Second, their physiological concentrations are 
normally quite constant, ranging from 135 to 
143 mM for sodium and between 3.3 and      
4.6 mM for potassium (28).  
To evaluate the idea, potassium and 
sodium were also quantified in all the reverse 
iontophoretic samples obtained in the fixed 
concentration and stepwise concentration 
change experiments discussed above and their 
extraction fluxes were determined. The 
essential requirement for the internal standard 
is that its extraction flux is independent of the 
target analyte concentration; in other words, 
that the transport number of the internal 
standard is constant and is not affected by 
variations in the analyte's subdermal level.  
This requirement was fulfilled by both sodium 
and potassium.  Figures 2 (c) and (d) show the 
transport numbers of the three cations (Li+, Na+ 
and K+) calculated using the JLi data in Figure 
2 (a) and 2 (b) and the corresponding measured 
values of JNa and JK.  It is apparent that the 
sodium and potassium transport numbers were 
indeed constant within each experiment, while 
that of lithium varied as anticipated in 
proportion to the drug's subdermal 
concentration.  
This finding is completely logical for 
sodium, which is present subdermally at a 
much higher concentration than lithium.  When 
lithium transports a slightly greater or smaller 
amount of charge, due to its subdermal level 
changing, therefore, sodium (as the major 
current carrier) is able to "take up the slack" 
without a significant impact on its transport 
number (18). On the other hand, for potassium, 
whose physiological concentration is much 
closer to lithium's therapeutic range, one might 
have expected some compensation between the 
transport numbers of the two cations.  That this 
is not the case may be explained by the fact 
that potassium is, in some respects, a more 
“efficient” charge carrier than sodium: that is, 
while sodium is 30 times more concentrated 
than potassium in the subdermal solution, the 
ratio of their extraction fluxes was only ~20, 
meaning that potassium has the significantly 
higher mobility of the two ions.  It is not 
simply concentration, therefore, which 
determines the absolute value of a transport 
number.  Unravelling the relationship between 
concentration, mobility, and other factors, 
which impact upon the manner in which the 
current is distributed among the available 
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charge-carriers, is an important future 
objective of iontophoretic research.  
The next step was to verify the validity of 
Equation 2.  The regressions shown in Figure 2 
(e) and (f) demonstrate the correlations 
between the ratio of lithium to sodium 
extraction fluxes (RNa) and either the lithium 
subdermal concentration, or the ratio of the 
subdermal concentrations of the two ions. 
When the corresponding regressions were 
performed for RK, the correlations were 
satisfactory, though smaller (r2 = 0.89 and 0.83, 
respectively), presumably because of the 
slightly higher variability observed in 
potassium fluxes as compared to those of 
sodium.  Nevertheless, overall, this component 
of the study demonstrated unequivocally that 
the internal standard concept works in vitro 
and may constitute a viable approach to 
normalize lithium iontophoretic extraction for 
drug monitoring purposes. 
 
C. Concentration-profile kinetic 
experiments 
Further experiments examined whether 
transdermal iontophoresis could be used to 
determine pharmacokinetic parameters non-
invasively. This was evaluated by simulating 
two classic plasma profiles in the subdermal 
compartment of the iontophoretic cells. It 
should be noted that the goal of these studies 
was to illustrate the versatility of reverse 
iontophoresis for non-invasive monitoring; 
there was no intention here to simulate “real” 
lithium pharmacokinetics, which can be 
complex (4, 29).  
(a) IV bolus 
The first kinetic profile considered was an 
IV bolus. Mono-compartmental kinetics were 
assumed. The model was characterized by an 
average volume of distribution of 4.54 ml (the 
mean subdermal compartment volume of 
diffusion cells) and a clearance of 1 ml/h (the 
syringe pump rate of perfusion). The dose 
“injected” was 4.96 µmoles. The subdermal 
concentration profile should therefore follow 
an exponential decay post-injection :  
tK
t
eeCC .0 .
−=  Equation 4
 
where Ct and C0 are the lithium subdermal 
concentration at a given time t and at t=0, 
respectively, and Ke is the elimination rate 
constant. Upon combination of (i) Equations 3 
and 4, and (ii) Equations 2 and 4, two testable 
hypotheses were defined for this experiment, 
namely: 
tK
Li
eeCJ .0 ..
−= γ  
 
tK
SI
eeCR .0
#
.. ..
−= γ  
Equation 5 
 
Equation 6
 
where the significance of JLi, RI.S., γ and γ# 
have been previously defined. 
Throughout these experiments, sodium and 
potassium extraction fluxes were constant, 
averaging 9.4 µmol/h (± 4%) and 0.55 µmol/h 
(± 11%), respectively. On the other hand, the 
lithium fluxes, in general, tracked the changes 
in its subdermal concentrations. Figure 3 
shows the lithium subdermal concentration, the 
lithium extraction flux and the ratios of 
extraction fluxes (JLi/JNa and JLi/JK) as a 
function of time post-injection. In general, 
good agreement with the model is observed. 
The subdermal concentration data allowed the 
reference values for the parameters 
characterizing the model to be determined 
(Table II). Clearance values estimated with 
both model-dependent and model-independent 
methods were very similar. These experimental 
parameters agreed well with the theoretical 
values cited above. 
Figure 3 reveals that the values of JLi, RNa 
and RK do not conform to the expected profiles 
(Equations 5 and 6) during the first hour of 
extraction. In fact, the profiles are reminiscent 
of an oral administration, for example, with a 
very fast absorption phase. After one hour, 
however, the three profiles decreased in 
parallel with the subdermal Li concentration. It 
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appears therefore, that during the first hour, JLi, 
RNa and RK reflect two concurrent processes: 
(i) the subdermal lithium kinetics, and (ii) the 
establishment of steady iontophoresis 
extraction fluxes across the skin. That is, until 
γ and γ# become constant, the JLi, RNa and RK 
profiles report on both processes. Once this is 
achieved, the extraction flux becomes directly 
and proportionally dependent on the subdermal 
concentration, and the slopes of the lines in 
Figure 3 are parallel. 
Figure 4 presents the values of γ and γ# as a 
function of time. A repeated measures 
ANOVA demonstrates that γ and γ# become 
constant from the third sampling period (after 
85 minutes of iontophoresis). Mean values for 
γ (68.8 ± 1.7 µl/h); γNa# (7.3 ± 0.2 M-1) and γK# 
(114.1 ± 4.2 M-1) were determined by linear 
regression through the data obtained          
post-85 minutes of iontophoresis. 
Linear regression of the semi-logarithmic 
data (after the third sampling period) in   
Figure 3 permitted the elimination rate 
constant (Ke) to be determined from the 
iontophoretic extraction data and compared to 
the reference value (Table II). In general, Ke 
was slightly under-estimated relative to that 
calculated from the decay of the subdermal 
 
Table II: Pharmacokinetic parameters determined in the bolus experiment (Mean ± SD, n=6). 
 
 r2 Ke T1/2 C0 b,c Vd b,c Cl b,c Cl b,d 
 ≥ (.10-3min-1) (min) (mM) (ml) (ml/h) (ml/h) 
CLi  Subdermal 0.99 4.2 ± 0.3 168 ± 14 1.01 ± 0.06 4.9 ± 0.3 1.22 ± 0.05  1.21 ± 0.04 
        
JLi 0.99 3.9 ± 0.2 180 ± 10 0.99 ± 0.06 5.0 ± 0.3 1.17 ± 0.02 1.21 ± 0.03 
RK 0.96 3.6 ± 0.3a 193 ± 15a 0.97 ± 0.06 5.1 ± 0.3 1.10 ± 0.07a 1.21 ± 0.09 
RNa 1.00 3.8 ± 0.2 181 ±   9 0.98 ± 0.06 5.1 ± 0.3 1.17 ± 0.04 1.22 ± 0.06 
 
a  Value significantly different from reference value obtained from the direct measurement of CLi (P<0.05) (Kruskal-
Wallis ANOVA on ranks) 
b  Values determined using γ, γ K # or γ Na #, respectively 
c 
   Calculated assuming a one-compartment model: Vd=Dose/C0, Cl=Ke.Vd 
d
    Model independent calculation using the corresponding area-under-the-curve (AUC) 
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Figure 3: Simulated lithium bolus administration (left panel) and a semi-logarithmic transformation
of the data (right panel). The solid squares are the subdermal lithium concentrations; the open
squares are the iontophoretic extraction fluxes of the drug (JLi).  The open circles and open triangles
are, respectively, the extraction flux ratios, RNa and RK. Each data point represents the mean ±
standard deviation (n=6). Solid lines of simple interpolation through the data are shown in the left
panel; the dashed lines in the right panel, on the other hand, are linear regressions. 
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concentrations, resulting in a predicted half-life 
that was 13-25 minutes longer. Nevertheless, 
overall, the agreement was really quite good. 
One possible source of the differences 
observed is the time required for the 
iontophoretic sampling. The data point at       
85 minutes, for example, reflects a moving 
average, so to speak, of the instantaneous 
values during the sampling period between    
70 and 100 minutes. On the other hand, the 
subdermal CLi was measured in a sample taken 
at exactly 85 minutes (i.e., the mid-point of the 
iontophoretic extraction period). An analogy 
may be drawn between measurements of 
urinary excretion rates and plasma 
concentrations. Clearly, when comparing 
kinetic parameters from the two types of 
measurement, the degree of error (difference) 
becomes greater as the sampling period 
increases. This fact has been recognized in the 
Glucowatch® with which glycemia is now 
assessed every 10 minutes such that very close 
tracking of glucose levels is possible. In the 
end, analytical sensitivity is the determining 
factor – for lithium, with the assay sensitivity 
and precision presently possible, 5-10 minute 
sampling intervals are feasible.  
The iontophoretic extraction data were 
next used to estimate additional 
pharmacokinetic parameters (including the 
clearance (Cl) and volume of distribution 
(Vd)). Equations 5 and 6 indicate that C0 can be 
found provided that γ and γ#, respectively, are 
known. Knowing C0, it is then straightforward 
to assess Vd (=Dose/C0) and Cl (=Ke.Vd). The 
first step, therefore, was to identify the values 
of γ and γ# to be used. Figure 4 shows that 
these coefficients of proportionality become 
reasonably constant after about 1.5 hours of 
iontophoresis, and the mean values from this 
point on are the logical choices for the 
determination of the pharmacokinetic 
parameters of interest (Table II). The Vd and 
Cl determined in this way are quite close to the 
reference values. While this type of calculation 
based on in vitro data is usefully illustrative, it 
remains to be seen in vivo the extent to which γ 
and/or γ# vary within and between subjects; 
that is, will it be necessary to determine γ 
and/or γ# for every patient, or will a population 
average be sufficiently precise for all subjects? 
In the former ease, of course, careful 
calibration with blood sampling would be 
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Figure 4: Proportionality constants γ and γ# (defined in Equations 3 and 2, respectively, and 
determined from the bolus experiment) versus time.  Each data point represents the mean ±
standard deviation (n=6). 
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necessary for each person in order to define the 
value of the constant(s) to be used. 
Self-evidently, the internal standard 
calibration approach leading to the deduction 
of γ# is envisaged as a means to completely 
avoid calibration with blood sample. The 
constancy of Na+ extraction in this work 
speaks to its considerable potential in this 
regard; on the other hand, potassium, which 
was also evaluated, yielded more variable 
results. Certainly with Na+, then, the approach 
could be useful for a therapeutic monitoring 
application during lithium therapy. Care is 
necessary with respect to the kinetics, 
however, as a finite time is required before γ 
and γ# reach stable values (Figure 4). Whether 
this delay is partly an artefact, caused by the 
experimental design in which Na+ and K+ 
extraction fluxes were stabilized before Li was 
“injected” into the subdermal solution, remains 
to be seen. In a recent study examining the idea 
of valproate monitoring by reverse 
iontophoresis, and using glutamate as an 
internal standard, the value of γ# was constant 
from the very first sampling period, even 
though the extraction fluxes had not stabilized 
by this time. It is important to note, in this 
case, that the two ions were introduced 
simultaneously into the subdermal 
compartment. It follows that, for a patient 
receiving chronic lithium therapy, it is 
reasonable to expect γ# to become constant 
more rapidly than that observed in the in vitro 
work presented here.  
(b) Constant rate infusion 
The second situation considered was a 
constant infusion (5.6 µmoles/hour) of lithium 
chloride into the subdermal compartment 
having Vd ~ 4.54 ml. The clearance (syringe 
pump rate of perfusion) was 4 ml/h. The drug 
concentration profile, in this case, is described 
by the Equation 7 (27, 30): 
)1(
.
)1( .0 eKeCC tKe
d
t
ss VKe
Ke
t
−− −=−=  Equation 7
 
which predicts that CLi will increase 
exponentially to a steady-state plateau, Css. 
Figure 5 shows that this plateau level        
(~1.3 mM) was attained after 3-3.5 hour of 
perfusion. When the subdermal concentration 
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Figure 5: Iontophoretic monitoring of lithium during a simulated constant infusion to steady-state.
The subdermal lithium concentration profile is represented by the solid squares and the line
through the data is a fitted curve according to Equation 7; the open squares are the iontophoretic
extraction fluxes of the drug (JLi) (data fitted to Equation 8).  The open circles and open triangles
are, respectively, the extraction flux ratios, RNa and RK (results fitted using Equation 9).  Each data
point represents the mean ± standard deviation (n=6). 
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profile was fitted to equation 7 (r2 ≥ 0.94, non-
linear regression), the following reference 
values were obtained; Ke = 0.014 ± 0.001   
min-1; T1/2 = 50 ± 4 min; Css = 1.32 ± 0.03 mM; 
Vd = 5.1 ± 0.3 ml; and Cl = 4.2 ± 0.1ml/h. 
Figure 5 also demonstrates that the 
iontophoretic extraction of Li flux and the 
extraction flux ratios (RNa and RK) also 
increased exponentially towards steady-state 
values, conforming to the following equations 
which result from the substitution of Equations 
3 and 2, respectively, into Equation 7: 
 
)1.( .tKssLi eeJJ
−−=  
)1.(. .tKss eeC
−−= γ  
 
)1.( ...
tK
ssSI
eeRR −−=  
)1.(. .# tKss eeC
−−= γ  
 
Equation 8 
 
 
Equation 9
The significance of JLi, RI.S., γ and γ# are as 
before; JSS and RSS represent the steady-state 
values of JLi and RI.S., respectively. 
Interpretation and analysis of the 
iontophoretic extraction flux data were more 
complicated than the IV bolus case. In the 
latter situation, the only “pharmacokinetic” 
process taking place in the subdermal 
compartment is drug elimination. In contrast, 
in the infusion scenario, there is both “input” 
and elimination; it should be recalled, 
furthermore, that the time to steady-state under 
these circumstances is on the order of four 
elimination half-lives. This relatively slow 
approach to steady-state means that the 
biphasic behaviour of JLi and RI.S. seen in the 
I.V. bolus situation is “lost” when the drug is 
perfused into the subdermal compartment. It is 
not that the biphasic phenomenon is no longer 
occurring, it is simply that the data are not 
sufficiently precise, nor were they acquired at a 
high enough frequency, to allow this behaviour 
to be observed. This conclusion is confirmed 
somewhat by the fact that fitting Equations 8 
and 9 to the data in Figure 5 is much better 
when the two first samples are omitted; after 
about an hour, however, the model fits the 
results very well. 
The evolution of γ and γ# with time is 
shown in Figure 6. It is first noted that the 
absolute values of these parameters are very 
similar to those observed in the I.V. bolus 
experiments (Figure 4), supporting the 
contention that these proportionality constants 
may show very small inter-individual 
differences. Also clear when comparing 
Figures 4 and 6, however, is that it takes longer 
for the values of γ and γ# to stabilize in the 
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Figure 6: Proportionality constants γ and γ# (defined in Equations 3 and 2, respectively, and
determined from the constant infusion experiment) versus time.  Each data point represents the
mean ± standard deviation (n=6). 
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infusion situation; a repeated measures 
ANOVA indicates that 2.5-3 hours are 
necessary, in fact. At this point, it was deduced 
that: γ=65 ± 14 µl/h, γK# =135 ± 43 M-1, and 
γNa# =7.6 ± 1.4 M-1. It is logical to suppose that 
the increased time for stabilization is due to the 
same phenomenon implicated in the I.V. bolus 
case, superimposed upon the fact that steady-
state kinetics are approached only quite slowly 
when the drug is infused into a compartment 
from which clearance is not rapid. 
The iontophoretic extraction fluxes become 
progressively more reflective of the subdermal 
kinetics with increasing time, therefore. When 
the iontophoretic data in Figure 5 are fitted to 
Equations 8 and 9, the values of JS.S., RS.S. and 
Ke obtained are very close either to the 
experimental results or to the theoretical value. 
Similarly, the derived values for clearance (Cl) 
are in excellent agreement with the reference 
value of 4.2 ± 0.1 mL/h. From the stable values 
of  γ and γ#, the calculated clearances were   
4.1 ± 0.1 (from JLi), 4.1 ± 0.2 (from RK) and 
4.1 ± 0.1 ml/hour (from RNa). 
Estimation of Ke from the iontophoretic 
extraction data was more challenging. This 
parameter was obviously underestimated when 
data from the earliest sampling times were 
included (Figure 7). When these initial results 
were omitted, the fitting procedure improved 
(r²≥0.8); for example, analysis of data from   
85 minutes onward resulted in values of Ke   
(in min-1) of 0.0095 ± 0.0003 (from JLi), 0.0091 
± 0.0009 (from RK) and 0.0091 ± 0.0005     
(from RNa). The “reference” value, it is 
recalled, was 0.014 min-1. Thereafter, if results 
only from the latter half of the experiment are 
fitted (Figure 7), the resulting Ke increased 
somewhat but not significantly, and the 
goodness-of-fit decreased. It is not clear 
whether, in this experiment, the iontophoretic 
fluxes could ever provide a better estimation of 
Ke. Once steady-state is achieved, of course, 
the sensitivity of the model to determine Ke is 
lost. It follows that there is a temporal 
“window of opportunity” for the estimation of 
Ke; long enough has to have elapsed so that the 
extraction fluxes have caught up with the 
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Figure 7: Values of Ke (mean ± SD; n=6) determined from the constant infusion experiment. Data
for JLi, RNa and RK (filled, open, and hatched bars, respectively) were fitted to Equations 8 and 9.
The results were calculated from the individual data obtained during the different time intervals
indicated on the abscissa. The dashed line at Ke = 0.014 min-1 indicates the “reference” value of
this parameter. 
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subdermal kinetics, but not so long that steady-
state is close to having been attained. Clearly, 
in this situation, the practical application to 
pharmacokinetic profiling will be limited. On 
the hand, the results demonstrate an effective 
means with which to determine noninvasively, 
and quite accurately, a drug’s clearance. 
In conclusion, the results presented here 
demonstrate that reverse iontophoretic 
monitoring of lithium is concentration-
dependent, and that quantitative information 
about the drug’s subdermal level can be 
obtained without a “blood” measurement via 
the use of Na+ and/or K+ as an “internal 
standard”. The iontophoretic extraction flux of 
Li, and the ratio of this flux to that of either 
Na+ or K+, tracks pharmacokinetic changes in 
the drug’s subdermal concentration rapidly and 
faithfully, allowing the remarkably 
noninvasive determination of certain 
pharmacokinetic parameters that are presently 
available only via plasma or whole blood 
measurements. 
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Notations 
J  Extraction flux (units: nmol/h) 
RI.S.  Ratio between lithium (Li) and internal 
standard (I.S.) extraction fluxes (JLi/JI.S.) 
CLi  Lithium subdermal concentration (units: 
mM) 
γ  Proportionality constant (units: µl/h) 
between JLi and CLi 
γ#  Proportionality constant (units: M-1) 
between RI.S. and CLi  
ta  Transport number of ion a 
Ke  Elimination rate constant (units : min-1) 
T1/2  Half-life (min) 
Ct  Concentration at a given time t (mM) 
Vd  Volume of distribution (ml) 
Cl  Clearance (ml/h) 
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Le monitoring non-invasif du lithium par ionophorèse inversée 
Une étude in vivo  
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Résumé 
Buts : Cette étude évalue in vivo les capacités de l’ionophorèse inversée à devenir une méthode non-
invasive de monitoring de la lithiémie et une alternative aux prélèvements sanguins. 23 patients 
souffrant de troubles bipolaires ou schizo-affectifs et sous lithiothérapie ont participé à cette étude.  
Méthodes : L’ionophorèse, réalisée sur l’avant-bras des volontaires, fut bien acceptée. Les échantillons 
ionophorètiques ont été analysés pour quantifier les ions lithium, sodium, potassium et calcium 
extraits à la cathode par électromigration. Un prélèvement sanguin classique a été prélevé afin de 
fournir les valeurs de référence du lithium et des autres électrolytes.  
Résultats : Les flux d’extraction du lithium varient proportionnellement avec les lithiémies sériques. 
En revanche, ceux du sodium, potassium et calcium étaient relativement constants. Aussi, ces 
électrolytes furent considérés comme de possibles standards internes pour la calibration de la méthode 
de monitoring du lithium. Il a été observé que le rapport des flux d’extraction était proportionnel à la 
lithiémie sérique et que seul le sodium, se comportait comme un standard interne acceptable. La 
population a ensuite été partagée aléatoirement en deux groupes distincts. Les constantes d’extraction 
ionophorétiques ont été déterminées d’après le premier groupe et utilisées pour prédire les lithiémies 
sériques du second groupe. La comparaison des valeurs prédites et des valeurs de références a 
démontré une excellente capacité prédictive. 
Conclusions : Cette étude prouve que l’ionophorèse inversée offre une méthode alternative et non-
invasive pour le monitoring de la lithiémie. 
 
Mots clés : Ionophorèse, Monitoring thérapeutique, Lithium, Extraction transdermique, Non-invasive 
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Abstract 
Reverse transdermal iontophoresis was investigated as an alternative and non-invasive method for 
lithium monitoring in vivo. Experiments were performed in 23 bipolar or schizo-affective patients. 
Lithium, sodium, potassium and calcium were efficiently extracted by iontophoresis. A conventional 
blood sample provided comparative reference values for the drug and other electrolytes. Lithium 
extraction fluxes were proportional to the corresponding serum concentrations. In contrast, sodium, 
potassium and calcium extraction fluxes were relatively constant, consistent with their stable blood 
levels. Normalization of the lithium extraction flux with that of sodium, which acted as an “internal 
standard”, permitted calibration of the monitoring procedure without the need for a blood 
measurement. This conclusion was then tested retrospectively by dividing the patient population into 
two groups of equal size. The reverse iontophoretic extraction data from the first subset were used first 
to establish the proportionality between lithium iontophoresis (or the relative electrotransport of Li and 
Na) and the lithium blood level (or the ratio of Li to Na systemic concentrations), and then second to 
predict lithium blood levels in the second subset of patients. An excellent predictive ability was 
achieved, with the use of the internal standard significantly reducing the confidence interval associated 
with the predicted value. In conclusion, reverse iontophoresis appears to offer a novel and accurate 
method for lithium monitoring. 
 
Keywords: Iontophoresis, Therapeutic drug monitoring, Lithium, Transdermal extraction, Non-
invasive 
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I. Introduction 
Fifty years after the first report of its anti-
manic effects (1), lithium remains a first choice 
mood stabilizer for preventing relapses in 
bipolar disorders (1-3).  It is also the only 
mood stabilizer for which a preventive effect 
on suicidal risk has been clearly shown (3,4). 
Regular lithium monitoring is essential to 
ensure efficacy and to prevent adverse effects 
(5). While steady-state plasma levels of the 
drug are achieved in a few days, a therapeutic 
response, in the treatment of manic episodes 
for example, is not observed until the two to 
three weeks post-initiation of treatment (6). 
Serum levels are monitored, therefore, on a 
weekly basis at the beginning of the treatment, 
then monthly or even longer intervals (7). 
More frequent supervision is required (i) in the 
absence of a satisfactory therapeutic response, 
(ii) in the presence of adverse effects or disease 
that affect drug disposition, (iii) to verify 
compliance (~40% poor compliance has been 
reported for bipolar patients (8)), or (iv) when 
using poly-pharmacotherapy involving 
potentially interacting drugs (9). Lithium 
monitoring involves a blood test which 
provides the so-called “Standardized 12 hour 
Li+ Serum Concentration”. That is, patients are 
subjected to a blood draw in the early morning, 
approximately 12 hours after the last dose of 
the day before, and prior to the first 
administration on the day of monitoring.  
It can be argued, therefore, that a 
completely non-invasive technique for lithium 
monitoring would facilitate compliance with 
treatment and improve the quality of life for 
bipolar patients. Saliva has been considered as 
an alternative matrix for lithium monitoring, 
but the broad inter and intra-individual 
variability of the saliva/plasma concentration 
ratio severely limits the usefulness of this 
approach (10,11). The skin offers, in principle, 
an extensive and accessible surface for drug 
sampling, and early research demonstrated the 
transdermal efflux of substances into collection 
patches by passive diffusion and secretion in 
the sweat (12-14). However, because these 
mechanisms are slow and inefficient, the long 
accumulation time required before the drug can 
be detected in the patch renders the method 
impractical for pharmacokinetic tracking (15). 
Transdermal flux can be significantly 
increased, however, by iontophoresis in which 
a low electrical current (<0.5 mA/cm2) is 
applied to the skin to facilitate polar and 
charged molecular transport through the barrier 
(16). Initially developed for transdermal drug 
delivery, iontophoresis has also been 
investigated as an alternative, non-invasive 
sampling technique. Indeed, The U.S. Food 
and Drug Administration recently approved a 
“reverse” iontophoretic device (GlucoWatch  
Biographer®, Cygnus Inc., CA, USA) that 
monitors glycaemia for 12 hours to help in the 
management of diabetes (17). The potential 
application of this technique for the monitoring 
of drugs and clinical markers has been recently 
reviewed (18). Two mechanisms of transport 
are involved in iontophoresis. Electromigration 
concerns the movement of ions, which carry 
charge across the skin and are driven 
(attracted) specifically towards the electrode of 
opposite polarity. Electroosmosis is a net 
solvent flow in the anode-to-cathode direction, 
which enables much improved permeation of 
neutral species (e.g., glucose), and further 
enhances cationic transport (19).  
Lithium monitoring by reverse 
iontophoresis has been investigated in vitro 
(20). This small, mobile and cationic drug is an 
excellent candidate for iontophoretic 
extraction. Lithium is transported by 
electromigration to the cathode (negative 
electrode), at a flux (JLi, nmol/h) described by 
equation 1: 
Li
Li
Li F.Z
I.tJ =  Equation 1
   
tLi and zLi are, respectively, the drug’s transport 
number and valence (+1), F is Faraday’s 
constant, and I is the current applied. The 
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transport number of a given ion (i.e. the 
fraction of charge transported through the skin 
by that ion) is proportional to its concentration 
when competing co-ions are present (21). This 
is obviously the case in reverse iontophoresis 
where the physiological milieu provides a 
panoply of competing co-ions. Under these 
circumstances, Equation 1 can be alternatively 
expressed as:  
JLi = γ. CLi Equation 2
 
where CLi is the subdermal concentration of 
lithium and γ is a constant. The in vitro 
investigation demonstrated a linear relationship 
between JLi and CLi (20). In vivo, on the other 
hand, it is important to correlate JLi with the 
serum concentration of the drug. While it is 
perhaps reasonable to suppose that the 
subdermal compartment is in rapid (or even 
instantaneous) equilibrium with the blood for a 
hydrophilic compound, such as lithium, it was 
nevertheless an important initial objective of 
this work to verify this hypothesis. To this end, 
only subjects undergoing chronic lithium 
therapy were admitted into the study, ensuring 
that any impact of slow drug distribution 
kinetics would be minimized. 
Iontophoresis is not a selective extraction 
process; in fact, all the ions present in the 
system compete for transporting the charge 
(22). Only those ions with a sufficiently high 
transport number will be efficiently extracted. 
The competitive nature of the extraction 
process and the complex composition of the 
“in vivo” milieu mean that transport numbers 
cannot be predicted a priori. If the efficiency 
of lithium extraction (characterized by the 
constant γ in Equation 2) shows wide inter- 
and intra-subject variability, a blood level 
calibration is obligatory. Such is presently the 
case for Glucowatch Biographer®, for 
example. In the case of therapeutic lithium 
monitoring, of course, reverse iontophoresis 
offers no advantage if calibration in this way is 
necessary. Additional objectives of the present 
study, therefore, were, on the one hand, to 
examine the degree to which γ varies between 
subjects and, on the other, to explore an 
“internal standard” concept (20,23,24) as a 
non-invasive means with which to standardize 
the reverse iontophoresis of lithium. 
An internal standard (I.S.) is defined as an 
endogenous compound which is present at 
relatively constant systemic concentration. It 
follows that the ratio of extraction fluxes 
JLi/JI.S. should be directly proportional to the 
ratio of subdermal concentrations, CLi/CI.S. In 
other words, and given that CI.S. is constant: 
JLi/ JI.S. = γ# . CLi Equation 3
 
Thus, the simultaneous, reverse 
iontophoretic extraction of Li and I.S. enables 
the concentration of the analyte of interest to 
be directly determined once γ# is known. The 
validity of this hypothesis has been 
demonstrated in vitro for lithium, using sodium 
and potassium as internal standards (20). Here, 
the internal standard calibration has been tested 
in vivo, and the suitability of the major cationic 
electrolytes: sodium, potassium, calcium, 
magnesium and ammonium, has been 
evaluated. 
 
II. Methods 
A. Materials 
L-histidine (USP, Eur.Ph.), sodium 
chloride (Eur.Ph.), silver wire 99.9%, silver 
chloride 99%, and platinum 99.9% were 
purchased from Sigma-Aldrich (Saint Quentin 
Fallavier, France). Deionized water (resistivity 
≥ 18.2 MΩ.cm) was used to prepare all 
solutions. 
 
B. Subjects 
Thirty ambulatory patients, diagnosed with 
bipolar or schizo-affective disorder, entered the 
study. The subjects were receiving chronic 
lithium therapy, at doses between 12 to          
36 mmol of Li per day (sulfate or carbonate 
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salt), for no less than 3 weeks. Of the original 
subjects enrolled, data from 6 patients were 
unusable (due to current interruption during 
iontophoresis, or to a leak from the collection 
chamber, or because of a missing blood 
sample). The results presented below, 
therefore, correspond to 24 patients              
(11 women, 13 men), aged 20 to 59 years.  
The clinical protocol was accepted by the 
internal review board of the Geneva University 
Cantonal Hospital. Informed consent was 
obtained from all participants. Patients arrived 
at 08.00 hr for their regular Li monitoring and 
were maintained in supine position throughout 
the study. The arm presenting the better venous 
accessibility was reserved for the standard 
monitoring procedure. The other forearm was 
used for reverse iontophoresis. A glass 
cylinder, which served as the cathodal 
compartment, was fixed to the forearm (at a 
site which had been cleaned with an alcohol 
swab) via a Teflon ring. Silicone grease was 
applied to avoid leaks. The ensemble was held 
firmly in place with medical tape (3M 9772L 
Foam Tape, 3M Health care, St Paul, MN, 
USA). The area of transport through the skin 
was 3.2 ± 0.4 cm2. The glass cell was filled 
with 1.2 mL of a 10 mM histidine aqueous 
solution (pH = 7.47) for 1 minute ; this liquid 
was then removed and refreshed and a 
Ag/AgCl electrode was then inserted into the 
solution and maintained at least 5 mm from the 
skin surface via a plastic top that covered the 
cell.  
The anodal chamber was either a similar 
glass cell, again equipped with a Ag/AgCl 
electrode, and filled with 62 mM NaCl 
solution, or a 32 cm2 commercially-available 
adhesive iontophoretic patch (Dispersive Pad, 
Iogel Medium, Iomed, Salt Lake City, Utah, 
USA). The anodal electrode was applied on the 
same forearm at approximately 10 cm from the 
glass cell holding the cathode. 
A Phoresor II Auto (PM850, Iomed) was 
used to deliver a constant direct current of    
0.8 mA. Four iontophoretic intervals of 30 
minutes were performed. At the end of each 
interval, the current was stopped and the 
electrode solutions were entirely removed and 
refreshed. The electrode solutions were 
analyzed for lithium and other cations as 
described below. 
A blood sample was taken between 90 to 
100 minutes post-initiation of iontophoresis 
and was reserved for subsequent analysis (see 
below). 
 
C. Analytical methods 
Ionic chromatography was used to quantify 
lithium, sodium, potassium, calcium and 
magnesium in the electrode chamber solutions. 
A Dionex DX-600 (Dionex, Voisins le 
Bretonneux, France) equipped with a GP-50 
pump, a AS-50 thermostated compartment 
(40°C), an ED-50 detector, a CS-16 cationic 
column and an Atlas suppressor was used. 
Data analysis was performed with a 
Chromeleon V.6.4 software (Dionex). Lithium, 
sodium and potassium were separated with a 
6.25 mM HMSA mobile phase flowing at 2 
ml/min and a suppressor current of 42 mA). 
Calcium and magnesium were separated with a 
25 mM HMSA mobile phase, a 1mL/min flow 
rate and a suppressor current of 83 mA). 
Lithium was quantified in the blood 
samples with an ion selective electrode (ISE) 
(Cobas Integra Model 700, Roche Diagnostics, 
Basel, Switzerland). Sodium, potassium and 
calcium were also quantified via ISEs 
(Synchron LX20 Beckman Coulter Inc, 
Fullerton, CA, USA). Magnesium and 
ammonium were assayed (Synchron LX20) 
with colorimetric and enzymatic tests, 
respectively. 
 
D. Statistics 
All data are shown as the mean ± standard 
deviation unless otherwise indicated. Data 
analysis and linear regression were processed 
with Graph Pad Prism V.3.02 (GraphPad 
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Software, Inc., San Diego, California, USA). 
Repeated measures ANOVAs were use to 
compare ion fluxes at different times. The level 
for statistical significance was set at P<0.05. 
All the regressions presented in this work were 
significant (P<0.0001) unless otherwise stated. 
Confidence intervals were calculated as 
described elsewhere (25).  
 
III. Results & Discussion 
The serum concentrations of lithium, 
sodium, potassium, magnesium, calcium and 
ammonium are presented in Figure 1.  Lithium 
levels fell in the range typical of patients being 
treated at the Geneva University hospital, with 
about 75% having steady-state concentrations 
between 0.5 and 0.9 mM.  The rest had lower 
levels, considered to be out of the therapeutic 
range, presumably due to poor compliance. 
Almost all serum concentrations of the other 
cations fell inside the normal physiological 
range. The coefficients of variation were 1.7% 
for sodium, 6.1% for potassium, 6.2% for 
magnesium, and 3.6% for calcium.  The 
corresponding figure for ammonium was over 
65%; consequently, no further attention was 
focused on this species. 
The extraction procedure began with a     
1-minute “washing” period during which 
current was not applied.  This “washing” step 
serves as an indicator of the existence (or not) 
of ion reservoirs in the more superficial layers 
of the skin (a point discussed further below).  
All “washing" samples contained detectable 
amounts of sodium and potassium, while 
lithium and calcium were detected in 22 and 
16, respectively, of the 24 samples analyzed.  
Magnesium was rarely detected (only 2 
samples). The amounts recovered (in nmol) 
were: lithium 14.4 ± 14.2, sodium 163 ± 212, 
potassium 106 ± 140, and calcium 10.5 ± 10.2.  
Iontophoresis was well-tolerated by the 
subjects.  Pricking sensations were frequently 
reported, being more noticeable at the anode at 
the start of each current interval. A mild, 
uniform and transient redness (typically 
resolved within a couple of hours) was 
observed at both electrode sites at the end of 
the protocol, similar to that which has been 
observed in previous work (26,27).  
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Figure 1: Box and whisker representation of the measured serum levels of lithium, sodium,
potassium, calcium and magnesium for 24 subjects. Dotted lines indicate the “normal” range
observed (28). Note that the range for lithium is that currently adopted by the Department of
Psychiatry of the Geneva University Hospital. 
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A. Ionic fluxes and transport 
numbers 
Lithium was efficiently recovered at the 
cathode for all patients.  In the first six 
subjects, the anode chamber was also analyzed 
for lithium and, although a measurable amount 
was found, the calculated flux never exceeded 
6% of that to the cathode. Subsequently, for 
practical reasons, disposable electrode patches 
were used for the anode in the remaining 
patients. 
Figure 2 shows the reverse iontophoretic 
extraction fluxes measured for each cation in 
the four successive 30-minute periods of 
current passage. The average lithium flux 
(Figure 2(a)) was 90.5 ± 37.9 nmol/h for the 
first sampling interval, and was significantly 
higher (P< 0.001) than those measured 
subsequently (average = 56.7 ± 18.6 nmol/h).  
This higher initial extraction, plus the fact that 
lithium was present in the pre-treatment 
"washing" solution, suggests the existence of a 
lithium reservoir in the skin and/or skin 
appendages.  Lithium has been found in 
cutaneous lesions (rashes and ulcers) and in 
biopsies obtained from the epidermis, dermis 
and subcutaneous adipose tissue of patients 
and guinea pigs chronically-treated with the 
drug (29,30).  It has also been demonstrated 
that lithium is secreted in sweat (31,32); thus, 
lithium found in the "washing" samples could 
also originate from this source. This apparent 
accumulation of lithium into the skin may lead 
to the creation of a reservoir, the magnitude of 
which is unrelated to the drug’s serum 
concentration.  Depletion of this reservoir 
would explain the early higher fluxes, and the 
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Figure 2: Iontophoretic extraction fluxes  (mean±SD; n=22 or 23) of lithium (JLi), sodium (JNa),
potassium (JK) and calcium (JCa) at each iontophoretic sampling interval. For JLi and JNa, the 0-30
value is significantly different from each of the subsequent samples. For JK, the 0-30 value differs
significantly from the two last samples. For JCa, the 0-30 value differs significantly from 30-60
sample which, in turn, differs significantly from the last measurement. 
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fact that the extraction then stabilizes at a 
constant, lower level.  In vitro, this 
phenomenon has not been observed (20); in 
that study, the skin used was obtained from 
pigs that had never been exposed to the drug.  
Under these circumstances, the extraction flux, 
not unexpectedly, increases towards its steady 
value.  Parenthetically, it is worth noting that a 
skin reservoir has also been identified for 
glucose (in this case due, it is believed, to 
metabolic breakdown of skin lipids) and that it 
is therefore necessary to deplete this material 
before calibration and operation of the 
Glucowatch® (27). 
Sodium extraction showed a different 
pattern (Figure 2(b)). The flux in the first 
interval (12.9 ± 1.6 µmol/h) was significantly 
less (P < 0.001) than the subsequently stable 
value achieved (15.8 ± 1.3 µmol/h). Potassium 
transport slightly but significantly (P ≤ 0.001) 
decreased from 4.4 (±1.2) to 3.8 (±0.8) nmol/h; 
the flux of this cation was more variable than 
sodium: coefficients of variation were 21% and 
8%, respectively, for the last three sampling 
periods.  Calcium extraction did not evolve in 
any clear pattern, the flux decreasing from 172 
(± 37) nmol/h at 30 minutes to 156 (± 24) at   
60 minutes, and finally reaching                   
185 (± 37) nmol/h at 2 hours. The coefficient 
of variation associated with calcium transport 
was also high (18%). Finally, magnesium 
extraction fluxes, while detectable, were below 
the limit of quantification. 
The a priori prediction of transport 
numbers remains challenging, particularly in 
reverse iontophoresis where the spectrum of 
potential charge carriers from within the body 
to the skin surface is very broad.  In general 
terms, though, it is known that the transport 
number of a specific ion will depend on its 
concentration and mobility, relative to the 
concentrations and mobilities of the competing 
ions in the system (22).  For this reason, of 
course, sodium is by far the principal charge 
carrier, being a mobile cation present at a 
much higher concentration than all others.  Its 
transport number (tNa = 0.54 ± 0.04) and that of 
lithium (tLi = 0.0018 ± 0.0006) were quite 
consistent with the corresponding values 
determined in vitro (20), in an experiment 
designed to mimic, to some extent, the in vivo 
situation examined in this work.  The transport 
number of potassium (tK = 0.13 ± 0.03) was 
higher than that measured in vitro            
(0.042 ± 0.006) (20), but was consistent with 
other values previously determined in vivo 
(33).  
 
B. Relationship between lithium 
serum concentrations and 
iontophoretic extraction fluxes 
A key practical objective of this study was 
to establish whether a clear relationship existed 
between lithium systemic levels and reverse 
iontophoretic extraction rates across the skin.  
Figure 3 illustrates how the serum lithium 
concentrations, measured approximately        
90 minutes after the initiation of current 
passage, compared with the drug’s 
iontophoretic fluxes for the four different,    
30-minute periods of extraction. Linear 
regression of these data resulted in the 
correlations in Table I.  While it is clear that 
there is a very poor relationship between the 
serum levels and the extraction data from the 
first sampling period, the correlations 
thereafter are excellent.  
The initially poor correlation is probably 
due, in large part, to the skin reservoir of the 
drug discussed above, and the fact that the 
amount of drug “stored” in the skin is not 
related to the instantaneous serum level.  It is 
necessary, therefore, for reverse iontophoresis 
to first "empty" this reservoir before it can 
reliably inform on the systemic concentration 
of the drug.  While it is certainly logical to 
expect that the iontophoretic flux should 
correlate better at times closer to the blood 
sampling, the terminal half-life of lithium     
(14 hours or more (5)) is sufficiently long that 
the concentration 30 minutes post-initiation of 
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reverse iontophoresis would only be slightly 
different from that an hour later, and 
unquestionably not so divergent as to explain 
the poor correlation with the first period of 
iontophoresis relative to the later 
measurements.   
Nevertheless, the results in Figure 3 and 
Table I are overwhelmingly positive in terms 
of establishing the in vivo relationship 
proposed between lithium levels and reverse 
iontophoretic extraction flux.  After an hour of 
current passage, excellent correlations were 
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Figure 3: Reverse iontophoretic extraction fluxes of lithium at (a) 30 minutes, (b) 60 minutes, (c)
90 minutes, and (d) 120 minutes, plotted as a function of the corresponding serum concentration
measured at 90-100 minutes post-initiation of current flow. Lines of linear regression are drawn
through the data (Equation 2), and the results of this analysis are in Table I. 
 
 
Table I: Linear regressions, at different times of iontophoresis, of (i) the extracted lithium flux (JLi) 
(data in Figure 3), and (ii) the ratio of extracted lithium and sodium fluxes (JLi/JNa), as a function of 
the serum drug levels, according to Equations 2 and 3, respectively.  Results are based on data from 
23 patients. 
 
  JLi  JLi/JNa 
  γ ± SE  Intercept r²  γ#Na ± SE Intercept r² 
Time (min)  (µl/h) (nmol/h)   (M-1)   
30  136 ± 38 11.5 0.38  11.7 ± 3.0  4. 10-4 0.42 
60  107 ± 11  -0.3 0.82    6.9 ± 0.4  5. 10-5 0.93 
90  100 ±   7  -4.0 0.91    6.1 ± 0.4 -2. 10-4 0.92 
120    92 ±   7  -0.2 0.90    5.6 ± 0.3  7. 10-5 0.93 
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obtained, with data both from patients with 
“normal” drug concentrations, within the 
therapeutic window, and from those with low 
lithium levels.  The challenge for a practical 
monitoring system will include, self-evidently, 
minimizing the time necessary to deplete the 
skin’s reservoir of lithium, and shortening as 
far as possible the time of current passage 
necessary for the reliable and sensitive analysis 
of the drug in the collection device. 
Figures 3(c) and 3(d) highlight statistically 
aberrant data (Grubbs’s test, P < 0.01), which 
were not used in the overall statistical analyses 
presented here, from two patients (for this 
reason, the number of subjects indicated in the 
results is sometimes slightly different).  The 
reverse iontophoretic extraction flux from one 
of these subjects was exceptionally high during 
the two later periods of iontophoresis; for the 
other volunteer, only the result in the final 
period was abnormally large.  Precise 
explanations for these observations are not 
available.  Perhaps, the former patient had an 
exceptionally large skin reservoir of the drug; 
possibly, the outlier for the second patient was 
the result of an accidental contamination.  
Clearly, additional studies, in much larger 
populations, will ultimately be necessary to 
provide information about intra- and inter-
subject variability, and potential sources of 
systematic and opportunistic error.    
The linear correlation between lithium 
extraction fluxes and the corresponding serum 
levels provides a quantitative measure of the 
proportionality constant (γ) linking the two 
variables (Equation 2).  The most direct 
evidence of the potential of reverse 
iontophoresis for lithium monitoring would be 
to demonstrate that γ varies very little both 
between different individuals and within each 
person tested.  That is, it would be possible 
then to derive a “global” value of γ that could 
be used in all patients, with high confidence, to 
convert their reverse iontophoretic extraction 
flux to a serum concentration.  The correlation 
based on the first 30-minute period of 
extraction would obviously be unacceptable 
(see Figure 4 and Table I): γ has a 28% 
coefficient of variation (CV).  However, for 
the next extraction period, the CV is down to 
10% and, in the two final intervals, it falls 
further to around 7%.  Compared to glucose 
extraction via the electroosmotic flow induced 
by iontophoresis, this level of variability in the 
proportionality constant is extremely low and 
reflects the relative stability of the transport 
numbers of the competing cations as described 
earlier.  In other words, the fact that the 
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Figure 4: Experimentally determined values of γ, the proportionality constant between JLi and CLi
(Equation 2) as a function of the duration of iontophoresis. 
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concentrations and mobilities of these ions are 
reasonably constant in vivo (or at least within 
sufficiently limited ranges such that their 
electrotransport kinetics are not too variable) 
means that the lithium extraction rates will 
respond to differences in the serum level in a 
rather consistent fashion from patient to 
patient.  If confirmed in a much larger group of 
subjects, the variability in γ may, in theory, be 
small enough to provide a general "calibration 
factor" for the direct therapeutic monitoring of 
lithium by reverse iontophoresis. 
 
C. Internal standard calibration 
Recognizing, however, that the 
straightforward approach proposed above 
carries with it an obvious risk of data 
verification, the “internal standard” calibration 
idea was examined.  The value of this strategy 
had been previously demonstrated in vitro, 
using as potential “internal standards”, the 
sodium and potassium cations.  
Physicochemically much like lithium, these 
ions are small and mobile and are principally 
transported across the skin by electromigration. 
A key criterion for any one of these cations 
to act as an “internal standard” for lithium is 
that their iontophoretic extraction fluxes be 
constant.  For sodium, this was indeed the 
case: its transport number, as the principal 
charge carrier, was high (~0.54), with a CV of 
around 8%.  In contrast, potassium and 
calcium revealed much more variable values 
for their transport numbers with CVs between 
15 and 25%.  Again, it is not entirely clear why 
such wide variability should have been seen.  
From a purely mechanistic standpoint, given 
the relatively constant systemic levels of these 
(albeit) secondary charge carriers, one would 
have expected more consistent behaviour (as 
was in fact observed for lithium).  A possible 
explanation lies in the fact that concentration 
gradients of calcium and potassium exist 
naturally in the epidermis.  According to the 
literature (34,35), calcium levels increase 
significantly from the basal epidermis to the 
outer stratum granulosum (SG) and then 
decline precipitously in the stratum corneum, 
while potassium also increases up to a 
maximum just below the SG before falling off 
dramatically across the most superficial layers 
of the barrier.  It is possible, therefore, that 
iontophoresis disturbs these ion concentration 
gradients (and presumably the 
intracellular/extracellular distribution of these 
ions as well) and provokes a subsequent 
attempt by the skin to re-establish the normal 
situation.  Consequently, it is conceivable that 
a competitive and dynamic situation is induced 
as iontophoresis extracts these ions to the 
surface and the skin strives to maintain the 
status quo.  Resolution of this point requires 
considerable further study. 
When the applicability of Equation 3 was 
tested using the measured systemic levels of 
sodium, potassium and calcium, and their 
respective reverse iontophoretic flux ratios 
with lithium, only the lithium/sodium ratios 
gave acceptable results.  Table I shows the 
linear regression results and clearly 
demonstrates that, after 30 minutes of 
iontophoresis, the ratio JLi/JNa should be 
usefully predictive of the serum lithium 
concentration (r2 > 0.92).  As observed for γ 
(the proportionality constant linking JLi to CLi), 
γ#, which links JLi/JNa to CLi, becomes very 
stable after the first iontophoresis period, with 
a low error.   In contrast, for potassium and 
calcium, the correlations between JLi/JK and 
CLi, and  JLi/JCa and CLi, were much less 
impressive: in the former case, r2 at 90 and  
120 minutes was 0.68 and 0.58, respectively; 
in the latter, the corresponding values were 
0.80 and 0.64.  It can be reasonably concluded, 
therefore, that sodium is by far the most 
suitable “internal standard” for "calibration-
less" lithium monitoring. 
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D. Prediction of serum lithium 
concentration 
In a final component of the investigation, 
the potential ability of the relationships derived 
to predict serum lithium levels from reverse 
iontophoretic extraction flux data was 
examined.  Retrospectively, the patients were 
divided into two groups: The first ten patients 
acted as a "training set", the data from which 
were used to develop population values of γ 
and γ# (specifically, from the regressions of JLi 
and JLi/JNa, respectively, against CLi).  The 
results of this exercise are summarized in the 
upper half of Table II.  With these 
proportionality constants, and the measured 
values of JLi and JLi/JNa in the remaining 
patients (the "test group"), their CLi were 
predicted and then compared to the actual, 
experimentally determined results.  The 
outcome of this exercise is presented first in 
the lower half of Table II, which contains the 
results of simple linear regressions between the 
predicted and measured values of CLi using the 
data from the two later periods of iontophoretic 
extraction.  The correlations are excellent and 
the slopes closely approach the theoretical 
values of unity (especially for final interval of 
iontophoresis). 
The approach was then better characterized 
by an inverse prediction procedure (25), which 
allowed the 95% confidence interval 
associated with each predicted value to be 
determined.   Figure 5 compares the 
experimentally measured CLi with the 
predicted results (together with the 
corresponding 95% confidence interval) based 
on the "training set" values of γ and γ#.  In the 
former case, the average confidence intervals 
at 1.5 hours and 2 hours of iontophoresis were 
±0.14 mM and ±0.19 mM, respectively.  When 
γ# was used, the corresponding values 
decreased to ±0.08 mM and ±0.11 mM. It is 
apparent that the predictability is rather good, 
with the iontophoretic extraction data at        
1.5 hours providing systematically narrower 
confidence intervals, independent of whether γ 
Table II: Upper part:  Linear regressions, at different times of iontophoresis, of (i) the extracted 
lithium flux (JLi) (data from Figure 3), and (ii) the ratio of extracted lithium and sodium fluxes 
(JLi/JNa), as a function of CLi, according to Equations 2 and 3, respectively.  Results are based on 
data from patients 1-10, the "training set".  Lower part:  Linear regressions between the predicted 
and measured values of CLi in patients 11-23 (the "test group") using either JLi or JLi/JNa and the 
values of γ and γ# derived from the "training set" for the two later periods of iontophoretic 
extraction.  
  
"Training set" 
  JLi versus CLi  JLi/JNa versus CLi 
  γ ± SE  Intercept r²  γ# ± SE  Intercept r² 
Time (min)  (µl/h) (nmol/h)   (M-1)   
  30  181 ± 69 -11 0.46  17.8 ± 5.4 -3. 10-3 0.57 
  60  112 ± 22    0 0.77    7.7 ± 0.8 -5. 10-4 0.92 
  90  114 ±  5 -12 0.87    7.1 ± 0.6 -8. 10-4 0.95 
120    90 ±  6    3 0.80    5.8 ± 0.7 -3. 10-5 0.91 
      
      
"Test group" 
  Prediction from JLi and γ  Prediction from JLi/JNa and γ# 
  Slope ± SE  Intercept r²  Slope ± SE Intercept r² 
Time (min)   (µM)    (µM)  
  90  0.83 ± 0.07  93 0.93  0.82 ± 0.08 122 0.91 
120  0.98 ± 0.09 -31 0.92  0.95 ± 0.08   23 0.93 
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or γ# was used for the prediction.  It is also 
important to point out that normalization of JLi 
with the sodium extraction flux almost halved 
the average confidence interval associated with 
the prediction of CLi, lending credibility and 
value to the “internal standard” calibration 
approach. 
However, close inspection of Figure 5 
shows that the confidence intervals for subjects 
18, 19 and 21 are large.  These patients had the 
lowest measured serum levels of lithium (0.16-
0.32 mM), whereas the "training set" data fell 
in the range 0.42-0.79 mM. Statistically 
speaking, therefore, these three subjects fell 
outside the predictive capabilities of the model 
(25), and this emphasizes the importance of 
considerably expanding the database to ensure 
that the "training set" encompasses the widest 
possible range of CLi.  Nevertheless, it can be 
argued that this exercise has been generally 
successful and positive, and that a clear value 
for the “internal standard”, in terms of 
improving data and in terms of predictive 
quality, has been demonstrated. 
 
IV. Summary 
This work shows that lithium can be easily 
extracted via transdermal iontophoresis in a 
concentration dependent manner. The 
variability of the extraction process is 
relatively low and has allowed (admittedly 
limited) predictive population extraction 
parameters to be estimated.  The use of sodium 
as an “internal standard” decreases the error 
associated with the predicted serum values. 
The results support the premise, therefore, that 
transdermal iontophoresis constitutes an 
alternative to blood sampling for lithium 
monitoring in vivo.  From a practical 
standpoint, considerable optimization of the 
approach is necessary, particularly with respect 
to maximizing extraction fluxes to shorten 
measurement times, and in terms of facilitating 
sample collection and analysis. 
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Figure 5: Comparison between measured CLi (bars) in the “test group” of patients and the 
predictions (mean ± 95% confidence interval) based upon the values of γ (open squares) and γ#Na
(filled circles) determined from the data of those patients (n=10) used as the “training set”. Panel
(a) shows the results based on the iontophoretic extraction fluxes (of Li+ and Na+) in the 60-90 
minute interval (n=13), panel (b) uses data from the 90-120 interval (n=12). 
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determining the relative levels of two 
substances present in a biological system. 
University of Geneva, June 22, 2001. 
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Résumé 
Buts : Cette étude propose une formulation gélifiée des chambres d’extraction par ionophorèse 
inversée. Facilitant son usage in vivo le gel doit être bon conducteur du courant et faciliter, autant que 
possible, l’étape analytique ultérieure. La formulation d’un gel polymérique (Pluronic F127) 
thermoréversible a été envisagée. 
Méthodes : Les expériences de ionophorèse ont été menées in-vitro sur peaux dermatomisées d’oreille 
de porc. Le compartiment subdermique contenait une solution physiologique, du sodium en 
concentration fixe ainsi que du lithium en concentrations thérapeutiques variables. Un protocole de 
dialyse à l’équilibre a été mis au point dans le but d’extraire du gel les composés collectés par 
ionophorèse. Les quantités extraites de lithium et de sodium ont été analysées. 
Résultats : Les résultats ont démontré in vitro (a) la faisabilité de l’extraction du lithium et du sodium 
dans un milieu d’extraction tamponné et gélifié avec du Pluronic F127 (20% m/m) et (b) qu’une 
technique simple de dialyse permet d’extraire les analytes du gel avant quantification. 
Conclusions : Cette étude démontre l’utilisation possible d’un gel thermoréversible comme milieu 
d’extraction pour des applications d’ionophorèse inversée in vivo. 
 
Mots-clés : Pluronic F-127, Polymère thermoréversible, Ionophorèse inversée, Lithium, Monitoring 
non-invasif 
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I. Introduction 
Reverse iontophoresis has been proposed 
as an alternative procedure for non-invasively 
sampling drugs through the skin. Previous 
work in vitro and in vivo has shown that 
lithium, a frequently monitored drug, could be 
quickly and efficiently extracted via 
iontophoresis (1,2). Furthermore, this research 
has suggested that pharmacokinetic parameters 
of selected drugs, such as half-life, may be 
estimated from the iontophoretically extracted 
flux profiles. The use of sodium as an internal 
standard to normalize lithium iontophoretic 
extraction flux has also been investigated (1,2). 
 
To date, simple aqueous solutions have 
been used to fill the electrode chambers on the 
skin surface into which the analyte of interest 
is extracted by iontophoresis. While this allows 
easy analytical chemistry, with little or no 
sample preparation, such vehicles are 
obviously not well adapted for practical 
purposes. In fact, the commercial development 
of iontophoretic drug delivery or sampling 
devices favours the use of gel or polymer 
formulations for the electrode compartments 
(3). A suitable vehicle for “in vivo” studies 
should combine a consistency that allows easy 
application and removal with appropriate 
conductive properties, as well as facilitating 
the subsequent analytical steps. It should be 
noted that an “off-line” assay of the drug is 
probably sufficient for drug monitoring and 
pharmacokinetic applications (i.e., an “on-
board” biosensor as, for example, in the 
GlucoWatch Biographer® is not obligatory (4)). 
The specific aim of this work was to 
formulate a gel or polymer-type collecting 
vehicle convenient for lithium reverse 
iontophoretic monitoring. As thermoreversible 
gels have been proposed as vehicles for 
iontophoretic drug delivery (5), it was decided 
to explore the possibility of using them as 
collection media for reverse iontophoresis. 
Pluronic F-127, a copolymer of 
polyoxyethylene and polyoxypropylene, (70/30 
w/w; M.W. 11500), forms a gel at room 
temperature thereby allowing easy topical 
application and removal (5,6). Subsequently, 
on cooling to 4°C, the gel becomes fluid 
allowing the potential for facile extraction of 
the analyte(s) accumulated therein during 
reverse iontophoresis. 
The first step was to formulate a 
conductive gel stable throughout the 
iontophoretic extraction period. Next, a 
dialysis procedure was developed to extract 
lithium and sodium from the collection gel. 
Finally, reverse iontophoresis of lithium (and 
sodium) was performed in vitro to compare the 
performance of the gel with that of a standard 
buffer solution. 
 
II. Materials and Methods 
Materials: 8 M LiCl solution was 
purchased from Fluka Chemie AG (Buchs, 
Switzerland). Pluronic F-127, Tris, Tris HCl, 
MOPS, NaCl, Ag wire 99,9%, AgCl 99%, Pt 
99,9% were obtained from Sigma-Aldrich 
(Saint Quentin Fallavier, France).  
Gel formulation: Pluronic F-127 gel was 
prepared by the cold method (7,8). The 
required amount of Pluronic F 127 was 
dispersed in a cold pH 7.4 (Tris 32 mM, 
MOPS 34 mM) buffer. The solution was 
continuously stirred at 4°C until it was clear. 
For the dialysis experiments (see below) 
appropriate amounts of lithium and sodium 
chloride were added to the fluid preparation at 
4°C. 
Skin: Porcine ears were obtained fresh 
from the local slaughterhouse and were 
cleaned under running cold water. The tissue 
from the inner face of the ear was then 
dermatomed (Air Dermatome, Zimmer TM, 
France Medica, Illkirch, France) to a thickness 
of approximately 750 µm.  The skin was either 
used at once or stored at –20°C for no longer 
than one month before use.  
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Reverse iontophoresis experiments: The 
skin was clamped between the two halves of 
vertical Franz diffusion cells (2,63 cm2). The 
lower half was kept at 37°C in a water bath 
and represented the anodal subdermal 
compartment, which was filled with a pH 7.4 
buffer (133 mM NaCl, 32 mM Tris, 34 mM 
MOPS). LiCl was added to this buffer at one of 
three concentrations (0.5; 0.9; and 1.4 mEq/l) 
spanning the therapeutic range of the drug. The 
upper half of the cell acted as the cathodal 
collecting chamber and was filled with 3 ml of 
either pH 7.4 buffer (32 mM Tris, 34 mM 
MOPS) or 20 % (w/w) Pluronic F-127 in the 
same buffer. The iontophoretic extraction 
consisted of a single 90 minutes application of 
direct constant current (1 mA) delivered via 
Ag/AgCl electrodes. At the end of the 
iontophoretic procedure, the cells were placed 
for exactly 6 minutes at -20°C to provoke the 
vehicle transition into the fluid phase. This 
time was fixed in order to ensure the same 
contribution of passive diffusion to the total 
transport in all replicates. The fluid receiver 
solutions were then homogenized and removed 
for analysis. 
Dialysis: A dialysis method was used to 
recover sodium and lithium from the Pluronic 
F-127 vehicles. Side-by-side Teflon cells (1 ml 
compartment volume and 0.79 cm2 dialysis 
surface) were employed. A cellulose dialysis 
membrane (Spectra/Por® 6, MWCO 2000, 
Spectrum® Laboratories, Inc., Rancho 
Dominguez, California, USA) was clamped 
between the two compartments with the 
assistance of two silicone rings. 1 ml of a fluid 
Pluronic receptor solution and 1 ml of a pH 7.4 
buffer solution (32 mM Tris and 34 mM 
MOPS) were placed into the donor and 
receiver compartments, respectively. The 
ensemble was kept at 4°C and continuously 
stirred for 12 hours. Other dialysis times were 
also studied (3, 6 and 24 hours). 
Assay: Lithium and sodium analysis were 
quantified by ion chromatography. A Dionex 
DX-600  (Dionex, Voisins le Bretonneux, 
France) equipped with a GP-50 pump (1 
ml/min), a AS-50 thermal compartment 
(25°C), a ED-50 detector (61 mA), a CS-16 
column and a 6 mM H2SO4 mobile phase were 
used. Peak integration was performed with a 
Chromeleon TM v.6.4. software.  Retention 
times of lithium and sodium were 6.8 and   
11.8 minutes, respectively. 
Statistics: Linear regressions were 
performed using Software Prism 4 (GraphPad 
Software, San Diego, CA). All regressions 
shown in this work were significant (P<0.01). 
Data are presented as the mean and standard 
deviation of at least 4 replicates.  
 
III. Results and discussion   
The effectiveness of the 20% w/w Pluronic 
F-127 buffer solution to act as an iontophoretic 
vehicle was first investigated. As well as a 
sufficient electrical conductivity, the 
formulation must permit the appropriate 
electrode reactions to proceed throughout the 
period of iontophoresis. Silver is reduced at the 
cathode, a reaction which requires only that the 
AgCl coating of the electrode is sufficient.  
Thus, the electrolytes added to the Pluronic 
solution (Tris and MOPS) served only for 
buffering and conductivity purposes. In 
contrast, silver oxidation occurs at the anode 
and the formulation must therefore provide 
enough chloride ions to avoid alternative 
electrochemistry and the precipitation of 
insoluble silver hydroxy species (9). It was 
found that 200 mM NaCl had to be added to 
the gel formulation to create a useable anodal 
vehicle. This rather high level was necessary 
because the slow diffusion kinetics in the gel 
meant that only the chloride ions relatively 
close to the anode were "available" to 
participate in the electrode reaction.  To avoid 
significant depletion, therefore, it was prudent 
to provide a high chloride content in the gel. 
Overall, the Pluronic F-127 solution 
worked very efficiently as a cathodal 
formulation into which lithium and sodium 
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(and, presumably, other cationic, neutral and 
zwitterionic analytes) could be extracted.  Its 
use as an anodal formulation, on the other 
hand, would require either a careful titration of 
the chloride concentration or the use of a salt 
bridge. 
Ion chromatography requires aqueous 
samples and it was therefore necessary to 
perform a simple dialysis procedure to separate 
the two cations from the polymeric vehicle. 
First of all, the linearity of the extraction 
process was verified. Reference gels were 
prepared to which different concentrations of 
lithium (20-100 µM) and sodium (2-10 mM) 
had been added. The ranges of concentrations 
were based upon the iontophoretic extraction 
efficiencies observed for the cations in 
previous work (1,2). After dialysis for            
12 hours, the cationic content of the aqueous 
solution was quantified. Both sodium and 
lithium extractions were linear (r2 > 0.99 for 
both cations). This simple procedure could be 
used, therefore, to process the samples. While 
other dialysis times (3, 6 and 24 hours) yielded 
equally good results, a 12 hour duration was 
preferred for practical reasons. The principal 
limitation of the approach was dilution of the 
analytes by the dialysis, a possibly critical 
Figure 1: Reverse iontophoretic extraction fluxes of lithium into either an aqueous or a gel
collection medium. The data represent the mean ± SD of 4 replicates. 
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Figure 2: Ratio of lithium to sodium extraction fluxes into either an aqueous or a gel collection
medium. The data represent the mean ± SD of 4 replicates. 
 
0.6 1.0 1.4
0.0
2.5
5.0
7.5
10.0
Buffer
Gel
Subdermal [Li] (mM)
10
3
*R
at
io
 J
Li
/ J
N
a
 Chapitre 5 : L’ionophorèse inversée du lithium : utilisation d’un gel polymérique 
thermoréversible pour la formulation des compartiments récepteurs 
84
issue for substances less efficiently extracted 
than lithium and sodium (in which case a 
method allowing direct quantification in the 
gel would be desirable).  
Reverse iontophoretic extraction of lithium 
and sodium demonstrated the performance of 
the gel as a cathodal receptor media. Control 
experiments used the same buffer but without 
the polymer. Figures 1 and 2 show the lithium 
extraction fluxes and the extraction flux ratio, 
JLi/JNa, for the gel and solution formulations as 
a function of the subdermal lithium 
concentration. A 2-way ANOVA 
demonstrated, for both JLi and JLi/JNa a 
significant dependence on concentration 
(p<0.001). There was no significant difference, 
however, between the extraction fluxes of 
either lithium or sodium into the gel and the 
solution.  Linear regressions between both JLi 
and JLi/JNa and the subdermal concentration of 
the drug are shown in Table I. The results are 
very similar and no statistical differences were 
found between the slopes and Y-intercepts in 
any case.  This shows that the F-127 gels can 
be successfully employed as vehicles in 
reverse iontophoresis and that the analytes 
were proportionally extracted by equilibrium 
dialysis before quantification by ion 
chromatography.  It was also noted that the use 
of sodium as an internal standard resulted in 
reduced variability, suggesting that some of the 
experimental error had been eliminated by this 
procedure. 
In summary, this study demonstrates the 
potential value of thermoreversible gel 
formulations as collection media for reverse 
iontophoresis applications. A simple technique, 
such equilibrium dialysis, can (if necessary) be 
used to separate the compounds of interest 
from the polymer to facilitate the subsequent 
analytical procedures. 
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Conclusions et perspectives 
 
Dans son ensemble, ce travail met en évidence le potentiel de l’ionophorèse inversée comme 
méthode alternative au prélèvement sanguin dans un contexte de surveillance thérapeutique. Le choix 
judicieux des deux molécules modèles, phénytoïne et lithium, a permis d’illustrer les capacités et les 
bénéfices de cet outil de diagnostique non-invasif. 
 
Aptitude de l’ionophorèse à réaliser un monitoring thérapeutique 
Quelle que soit l’ionisation de la molécule (cationique pour le cas du lithium, anionique et 
non-ionisée pour la phénytoïne), et le mécanisme d’extraction (électromigration ou électroosmose) de 
bonnes corrélations ont été obtenues entre les concentrations subdermiques et les quantités extraites 
par ionophorèse. Cette étude confirme aussi que le meilleur candidat à l’extraction ionophorètique est 
de petite taille. De plus pour des raisons analytiques de quantification dans les extraits, les meilleurs 
candidats sont des médicaments en concentrations thérapeutiques importantes dans la circulation 
systémique et si possible bien ionisés de façon à profiter du mécanisme d’extraction transdermique le 
plus efficace qui soit : l’électromigration. 
Des différences notables ont été observées entre ces deux principes actifs. Par exemple, les 
délais nécessaires à la stabilisation de l’extraction sont très différents : 6h pour le lithium et 15h pour 
la phénytoïne. Ces résultats sont notamment dûs aux différences physicochimiques des deux 
médicaments. Sans doute la taille et la lipophilie de la phénytoïne sont telles qu’elles deviennent des 
facteurs déterminant dans la lente stabilisation du flux d’extraction ionophorétique. Cependant, des 
corrélations satisfaisantes (r²≥0.80) ont été obtenues après 1h30 pour le lithium, et 4 à 6h pour la 
phénytoïne, ce qui laisse envisager des temps d’application plus courts. Mais seules des études 
complémentaires in vitro puis in vivo pourront permettre de confirmer ces résultats. 
Cela a été le cas pour le lithium. L’étude préliminaire réalisée in vivo sur 23 patients confirme 
que l’extraction du lithium est bien linéairement dépendante de la lithiémie sérique (r²>0.9) après 60 
minutes d’extraction. Cette étude souligne aussi la faible variation inter-individuelle de l’extraction 
ionophorètique du lithium. Ces résultats laissent envisager le développement d’un système 
ambulatoire complètement non-invasif par voie transdermique nécessitant, au préalable, une étape 
d’optimisation opérationnelle et analytique. 
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Mesure des concentrations libres de principes actifs par ionophorèse 
Il a été montré que seule la fraction libre de la phénytoïne est extraite, le complexe 
phénytoïne/albumine étant trop imposant pour traverser les barrières successives de la peau. 
L’ionophorèse inversée a démontré ses capacités à suivre les modifications de la fixation protéique 
(par exemple : une hypoalbuminémie, une interaction médicamenteuse, …). Ceci souligne l’intérêt 
particulier de la technique pour des médicaments dont la fixation est dépendante de la concentration 
thérapeutique (par exemple : acide valproique). 
 
Aptitude de l’ionophorèse à suivre des profils pharmacocinétiques 
Pour un médicament aussi mobile que le lithium, les flux d’extraction ionophorètiques suivent 
rapidement les changements apportés aux concentrations subdermiques. Pour des médicaments dont 
les propriétés sont proches de celles du lithium, l’ionophorèse démontre, in vitro, un fort potentiel pour 
la réalisation d’études pharmacocinétiques. L’accès à la constante d’élimination (ainsi qu’à la demi-
vie) de manière complètement non-invasive constitue un atout important de cette technique. De plus, 
dès lors que les constantes d’extraction ionophorètiques sont connues, la technique permet l’accès aux 
autres paramètres. Nécessairement, d’autres études in vitro et in vivo devront confirmer ces résultats 
encourageants pour la réalisation d’études pharmacocinétiques aussi peu invasives que possible. 
 
Calibration pour rendre la technique complètement non invasive 
 Dans un contexte de monitoring thérapeutique, ne nécessitant classiquement qu’une seule 
prise de sang, la méthode ne serait d’aucune utilité clinique si elle nécessitait une calibration invasive. 
Les résultats in vivo de monitoring transdermique montrent que l’extraction du lithium est efficace et 
peu sensible aux variations inter-individuelles laissant envisager qu’une calibration n’est pas 
nécessaire. Néanmoins, une calibration par le sodium a permis de réduire sensiblement l’erreur sur les 
valeurs prédites de lithiémie. Ces résultats préliminaires restent à être confirmés sur une population 
plus vaste. Pour beaucoup d’autres médicaments moins mobiles, la calibration pourrait s’avérer 
indispensable. Cette étude démontre, in vitro et in vivo, la validité du concept de calibration par un 
« standard interne », rendant la technique complètement non-invasive. Son utilisation toujours 
satisfaisante, place le sodium comme un candidat de choix. Néanmoins, le choix d’un standard interne 
restera un challenge pour chaque couple médicament/standard interne. Des études approfondies 
devront estimer la variabilité de l’extraction du standard interne et son insensibilité vis-à-vis des 
changements de concentrations subdermiques du médicament. Inévitablement, l’optimisation de cette 
approche nécessitant la quantification des flux d’extraction des deux analytes passera par un 
développement analytique plus complexe. 
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